Drug, bio-affecting and body treating compositions inventions 09/08

20080234178 - Compositions and methods for treating immune system mediated diseases: The present invention is directed to compositions and methods for treating immune system mediated disease. In particular, certain embodiments of the present invention use BH3 mimetic therapy as an efficacious treatment of the effector phase of RA wherein the compositions and methods of the present invention markedly reduce the level... Agent: Husch Blackwell Sanders LLP

20080234176 - Modified peptides and their uses: A modified pro-α chain comprising a triple helix forming domain linked to at least an N-terminal domain, the N-terminal domain containing a polypeptide from at least part of a laminin glycoprotein or secretory leukocyte protease inhibitor. The pro-α chain may form part of a procollagen molecule that has the N-terminal... Agent: Bose Mckinney & Evans LLP 2700 First Indiana Plaza

20080234179 - Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the... Agent: Novartis Corporate Intellectual Property

20080234175 - Process for designing inhibitors of influenza virus structural protein 1: Disclosed are methods and compositions useful in identifying inhibitors of influenza virus, such as influenza A and B virus. Also disclosed are methods for preparing compositions for administration to animals, including humans infected with or to protect against influenza virus.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080234177 - Targeting-enhanced activation of galectins: Lectin-binding proteins and their therapeutic use. In particular, described are the targeting and targeting-enhanced multimerization and activation of galectins. Provided is a galectin-conjugate including at least one galectin molecule conjugated to a non-galectin cell targeting means. Exemplary targeting means include targeting means able to bind EGP2, a pancarcinoma-associated cell surface... Agent: Trask Britt

20080234181 - Antisense guanidinium peptide nucleic acid (gpna) oligonucleotides as antitumor agents: A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In... Agent: Barbara E. Johnson, Esq.

20080234180 - Use of sulgliocotide for the treatment of mucositis: Use of sulgliocotide in the treatment or prevention of mucositis.... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20080234182 - Blockers of pore-forming virulence factors and their use as anti-infectives: This invention provides a new generalized method for screening, identifying, selecting and designing symmetry-based compounds useful for blocking pores or prepores formed by pathogenic agents including bacteria, viruses, fungi, parasites, and other proteins capable of forming pores on cellular membranes as a step in the pathogenic mechanism of the agent.... Agent: Hogan & Hartson L.L.P.

20080234188 - Antimicrobial peptides: Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.... Agent: Myers Bigel Sibley & Sajovec

20080234183 - Cell penetrating peptides: The present invention relates to a method for predicting or designing, detecting, and/or verifying a novel cell-penetrating peptide (CPP) and to a method for using said new CPP and/or a novel usage of a known CPP for an improved cellular uptake of a cellular effector, coupled to said CPP. Furthermore,... Agent: Andrew K Gonsalves Nixon Peabody

20080234199 - Chemical compounds: Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080234192 - Compositions and methods of use for treating cardiovascular disease: In one aspect, the present invention provides isolated oxidation resistant mutant apoA-I polypeptides comprising an amino acid sequence substantially homologous to SEQ ID NO:4, the mutant apoA-I polypeptide comprising a combination of: (1) a conservative amino acid substitution at residue Tyr192; and (2) at least one conservative amino acid substitution... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080234190 - Glial mitogenic factors, their preparation and use: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors.... Agent: Klauber & Jackson

20080234194 - Growth factor mediated cosmeceuticals and use thereof to enhance skin quality: It has been discovered that vascular endothelial growth factor (“VEGF”) promotes migration of activated (but not differentiating) keratinocytes to skin. This growth factor specifically increases migration of keratinocytes of the “wounded skin” phenotype but does not have significant effects upon differentiated keratinocytes. It also increases collagen deposition and reduces wrinkles,... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080234187 - Human circulating cytokine cc-1: Cytokine CC-1 having the amino acid sequence according to SEQ ID No. 6 and its biologically active fragments and/or derivatives, in particular amidized, acetylized, phosphorylized and/or glycosylized derivatives.... Agent: Jacobson Holman PLLC

20080234191 - Human complement c3 derivates with cobra venom factor-like function: A modified human complement C3 protein (C3) is disclosed comprising a substitution of a portion of a human C3 protein, with a corresponding portion of a Cobra Venom Factor protein (CVF) which results in a human C3 protein with CVF functions, but with substantially reduced immunogenicity. Advantageously, the C3 protein... Agent: Morrison & Foerster LLP

20080234186 - Long-acting follicle stimulating hormone analogues and uses thereof: This invention provides FSH analogues having increased serum half-life relative to FSH. This invention also provides related compositions and methods for increasing fertility, egg production and spermatogenesis in a subject.... Agent: John P.white, Esq. Cooper & Dunham LLP

20080234200 - Method of treatment of a metabolic disease using intranasal administration of exendin peptide: Methods for treating metabolic diseases are described for intranasal delivery of an exenatide, comprising an aqueous mixture of exendin, and a delivery enhancer selected from the group consisting of a solubilizer, a chelator, and a surfactant, and the pharmaceutical formulations used therein.... Agent: Nastech Pharmaceutical Company Inc

20080234197 - Method(s) of stabilizing and potentiating the actions and administration of brain-derived neurotrophic factor (bdnf): A method of stabilizing and potentiating actions and administration of neurotrophins such as brain-derived neurotrophic factor (BDNF), neurotrophin-3, neurotrophin-4, and nerve growth factor and their receptors by using in coupling conjugation with polyunsaturated fatty acids (PUFAs) in the prevention and/or treatment of obesity, type 2 diabetes mellitus, metabolic syndrome X,... Agent: Undurti N Das

20080234198 - Selective vpac2 receptor peptide agonists: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20080234195 - Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations: The present invention relates to therapeutic, cosmetic, and nutraceutical applications for eggshell membrane, processed eggshell membrane preparations and eggshell membrane isolates. The invention is directed to treating a mammal that will benefit from the administration of naturally occurring material found in eggshell membrane, processed eggshell membrane, eggshell membrane isolates and... Agent: Hoffmann & Baron, LLP

20080234196 - Treatment and prevention of vascular dementia: The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080234189 - Use of a composition: A method of treatment of a mammal suffering from an inflammatory condition or a cancer includes administering an anti-inflammatory protein or a peptide fraction of the protein having at least one repeating unit, the protein being selected from a group of proteins designated Eap (Extracellular adherence protein). The inflammatory condition... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080234185 - Use of dmbt1 for capturing sulphate and phosphate group exposing agents: Disclosed is the use of DMBT1, or of the nucleic acid encoding it, for the manufacture of a medicament for the treatment of a patient suffering from a disease caused by an agent, which possesses at least one accessible sulphate and/or at least one accessible phosphate group, uses of DMBT1... Agent: Birch Stewart Kolasch & Birch

20080234184 - Vectors for the co-expression of membrane domains of viral envelope proteins and uses thereof: The present invention discloses a vector for the coexpression of membrane domains of the envelope proteins of a virus, and also a method for producing homo- and/or hetero-oligomers of these domains. This vector comprises at least one region for replication and for maintenance of said vector in the host cell;... Agent: Mckenna Long & Aldridge LLP

20080234193 - Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.... Agent: Nektar Therapeutics

20080234201 - Bh3 peptides and method of use thereof: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080234202 - Non-natural amino acids and neurotensin analogues: This invention relates to methods of synthesis of amino acid analogs contained within peptide sequences that is adapted for preparation of peptides containing analogs of basic amino acids lysine and arginine.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080234204 - Methods for evaluating and implementing prostate disease treatments: Provide is a method for evaluating test agents as candidates for treating prostatic diseases, including benign prostatic hyperplasia (BPH) and androgen dependent and androgen independent prostate cancer. The method comprises providing a mouse comprising a human prostate primary xenograft, where the xenograft contains blood vessels that include human endothelial cells,... Agent: Hodgson Russ LLP The Guaranty Building

20080234203 - Use of substances having oxytocin antagonistic properties: The present invention relates to uses of a substance having oxytocin antagonistic properties and to methods of treatment comprising administration of a pharmaceutically effective amount of said substance.... Agent: Foley And Lardner LLP Suite 500

20080234205 - Antineoplastic peptides: e

20080234206 - Prodrugs of phentermine: The invention relates to compositions of amino acid and peptide conjugates comprising phentermine. Phentermine is covalently attached to at least one amino acid via its amine group to the N-terminus, the C-terminus, a side chain of the peptide carrier. Also discussed are methods for treating obesity.... Agent: Darby & Darby P.C.

20080234208 - Medical composition containing ginseng secondary glycosides, its preparation method and application: Medicinal composition containing ginseng secondary glycosides, its preparation method and application. The present composition contains mainly, as active ingredients, the ginsenoside with protopanoxadiol as aglucone (ginsenoside Rg3) and the ginsenoside with protopanoxatriol as aglucone (ginsenoside Rg2 and ginsenoside Rh1). It is prepared from the ginseng genus of plants through extracting,... Agent: Wolf Greenfield & Sacks, P.C.

20080234207 - Pharmaceutical composition for preventing and treating diabetes or glucose control abnormality comprising ginsenosides: The present invention relates to a composition for preventing or treating diabetes or blood glucose control abnormality comprising gisenosides Rg3, Rg5, and Rk1 from natural substances; a use of a mixture comprising gisenosides Rg3, Rg5, and Rk1 for the manufacture of a medicament for preventing or treating diabetes or blood... Agent: Birch Stewart Kolasch & Birch

20080234209 - Derivatives of asimadoline with covalently bonded acids: The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition,... Agent: Morrison & Foerster LLP

20080234210 - Anti-fungal composition: The present invention relates to an improved antifungal composition, to a process for preparing it and to its use as a preservative.... Agent: Nixon & Vanderhye, PC

20080234211 - Decladinosyl-macrolides with anti-inflammatory activity: The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides lacking cladinose sugar substituted at the C-3 position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080234222 - Charge reversal of polyion complexes: An ionic polymer is utilized in “recharging” (another layer having a different charge) a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The resulting recharged complex can be formed with an appropriate amount of positive or negative charge such that the resulting complex has the desired... Agent: Mirus Corporation

20080234219 - Compositions and methods for increasing bone mineralization: A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.... Agent: Marshall, Gerstein & Borun LLP

20080234215 - Dna composition and uses thereof: A plasmid DNA that encodes one or more antigenic genes operably linked to a promoter and a truncated retroviral 3′ LTR exhibits both enhanced safety and acceptable efficiency of expression of antigenic proteins.... Agent: The Law Offices Of Valerie E. Looper

20080234217 - Inhibitor nucleic acids: The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an... Agent: Ropes & Gray LLP

20080234212 - Materials and methods for treatment of allergic disease: siRNA molecules are disclosed which target the transcription factor STAT6 and repress the expression of STAT6 mRNA, STAT6 protein and STAT6 function in lung cells. The use of STAT6 specific siRNA molecules in the treatment of allergic diseases of the respiratory tract such as asthma and rhinitis is disclosed.... Agent: Kenneth I. Kohn Kohn & Associates

20080234220 - Methods and compositions for reducing viral genome amounts in a small target stem cell: Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target... Agent: Casimir Jones, S.c.

20080234214 - Oligonucleotide-containing pharmacological compositions and their use: The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20080234213 - Oncogenic regulatory rnas for diagnostics and therapeutics: A method of identifying regulatory RNAs, including miRNAs, using insertional mutagenesis to generate tumors in mice and determining the human orthologs is disclosed. Further, specific miRNA sequences are identified. The causal nature and expression patterns of these regulatory RNAs and miRNAs in human tumors demonstrate their utility in diagnosis and... Agent: Perkins Coie LLP

20080234218 - Sirna for inhibiting il-6 expression and composition containing them: Disclosed is a double-strand siRNA capable of suppressing interleukin-6 (IL-6) expression, and a pharmaceutical composition containing the same. The siRNA of the present invention and the pharmaceutical composition containing the same may be useful to treat inflammatory diseases, autoimmune diseases, neoplasmic disease and central nervous system diseases, which are all... Agent: Greenlee Winner And Sullivan P C

20080234216 - Tgf-beta type receptor cdnas encoded products and uses therefor: DNA encoding TGF-β type III receptor of mammalian origin, DNA encoding TGF-β type II receptor of mammalian origin, TGF-β type III receptor, TGF-β type II receptor and uses therefor.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080234221 - Transfection agents: The present invention provides compounds, compositions and methods that enhance the transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function... Agent: Townsend And Townsend And Crew, LLP

20080234223 - N4 modifications of pyrimidine analogs and uses thereof: The present invention relates to N4 carboxylester or ester derivatives of pyrimidine analogs with increased stability, solubility, and bioavailability. Also disclosed are methods of using these compounds for targeted drug delivery and combination therapy.... Agent: Hogan & Hartson Suite 1400

20080234224 - External preparation for skin: The present invention provides an external preparation for skin, which comprises a multi-branched polysaccharide derivative with multi-branched polysaccharide skeleton consisting of saccharides as constituent units, wherein at least one of hydroxyl (OH) groups in the multi-branched polysaccharide skeleton is substituted by OR (wherein R represents a hydrogen atom, a hydrocarbon... Agent: Sughrue Mion, PLLC

20080234225 - Method of treatment: A method and composition for preventing the formation of lesions in a patient having a site of inflammation by the use of a cromolyn compound. The cromolyn compound is used with a composition containing penetrating aids.... Agent: John Lezdey & Associates

20080234227 - Dextran functionalized by hydrophobic amino acids: The invention relates to a dextran functionalized by at least one hydrophobic alpha-amino acid radical, said alpha-amino acid being grafted or bonded to the dextran by a bonding arm and a functional group. A hydrophobic amino acid radical is understood as being the product of coupling between the amine of... Agent: Oliff & Berridge, PLC

20080234226 - Use of iron(iii) complex compounds for the preparation of a medicament for oral treatment of iron deficiency states in patients with chronic inflammatory bowel disease: The use of iron(III) complex compounds with carbohydrates or derivatives thereof for the preparation of a medicament for oral treatment of iron deficiency states in patients with chronic inflammatory bowel disease, in particular Crohn's disease and colitis ulcerosa, is disclosed.... Agent: Rankin, Hill & Clark LLP

20080234228 - Boronic acid salts: Salts of a peptide boronic add drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080234229 - Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders: The present invention is directed to compounds having the structure Formula (I) wherein R1, R2, R3, R4, R5 and m are as defined herein. The compounds of this invention are novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders in mammalian subjects. These compounds are also... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080234230 - Pharmaceutical composition for regulation of pancreatic juice secretion comprising a lpa receptor modulator: Pharmaceutical composition for regulation of pancreatic juice secretion characterized by comprising a lisophosphatidic acid (LPA) receptor modulator. Since an LPA receptor modulator has an effect of regulating the secretion of pancreatic juice, a compound acting on this receptor is useful in treating diseases in association with disorders in pancreatic juice... Agent: Sughrue-265550

20080234231 - Hiv integrase inhibitors: The present invention features compounds that are HIV integrase inhibitors and may be useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080234232 - Methods and compositions for targeting afap: Embodiments of the invention are directed to methods and compositions for inhibiting activation of cSrc by human actin filament associated protein (AFAP). Libraries and methods of screening compositions for inhibitive activity are also provided. Also provided are methods of treating cancer. Cancer may be, for example, but is not limited... Agent: Buchanan Ingersoll & Rooney PC

20080234233 - Medicament for treatment of neurodegenerative diseases: ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a... Agent: Greenblum & Bernstein, P.L.C

20080234234 - Compounds to promote regeneration of bone marrow: Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds to promote regeneration of bone marrow from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts.... Agent: Faegre & Benson LLP Patent Docketing

20080234235 - Synthesis of polyanhydrides: wherein compound (I) can be polymerized to provide a polymer that contains therapeutically active compounds. In the compounds of the invention, each R1 is group that will provide the therapeutically active compound upon hydrolysis of the polymer; each X is independently an ester linkage or an amide linkage; and R2... Agent: Viksnins Harris & Padys Pllp

20080234237 - Quinolone and tetrahydroquinolone and related compounds having nos inhibitory activity: The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for... Agent: Clark & Elbing LLP

20080234236 - Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist: Disclosed are methods of preventing adverse clinical events in a patient undergoing a percutaneous coronary intervention procedure or a peripheral percutaneous interventional procedure comprising administering a therapeutically effective amount of a thrombin receptor antagonist, such as SCH 530348, to the patient. Administration of a loading dose of about 40 mg... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080234238 - Pharmaceutical product containing progestin, genistein, and vitamin d compound: A pharmaceutical product comprising multiple daily sequential dosages, said product comprising a progestin and genistein, and optionally a Vitamin D compound. Genistein is preferably at least 20 mg, and more preferably 50-80 mg. The progestin is selected from the group consisting of norgestimate in the range of 0.18-0.25 mg, levonorgestrel... Agent: Jenner & Block, LLP

20080234239 - Topical composition: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.... Agent: Dykema Gossett PLLC

20080234240 - Extended use combination comprising estrogens and progestins: A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired period of time longer than 21-28 days comprising a first composition containing at least one estrogen and/or at least one progestin in a predetermined amount to be administered in the first 21-28 days and a second composition which... Agent: Millen, White, Zelano & Branigan, P.C.

20080234241 - Melanogenesis inhibitors and whitening agents comprising ergosterol derivative and compositions containing ergosterol derivative: It is intended to provide a substance which is efficacious in whitening sun-burnt skin after UV irradiation and preventing, ameliorating and treating skin pigmentation (for example, spots and freckles caused by sunburn, liver spots) and compositions containing the same. Melanogenesis inhibitors and whitening agents comprising an ergosterol derivative represented by... Agent: Brooks Kushman P.C.

20080234242 - Nitrate esters of corticoid compounds and pharmaceutical applications thereof:

20080234243 - Method of treating amyloidosis mediated diseases: The compounds of the present invention can be used to inhibit formation of beta-amyloid protein. The present invention provides methods of preventing, delaying onset of, or treating diseases or conditions characterized or mediated by amyloidosis. In particular, the present invention is useful for preventing, delaying onset of, and treating Alzheimer's... Agent: King & Spalding LLP

20080234244 - Cucurbitacin b and uses thereof: The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass methods of developing a therapeutic that comprises a... Agent: Evan Law Group LLC

20080234245 - Angiostatic agents for controlling choroidal neovascularisation after ocular surgery or trauma: Compositions of angiostatic agents for treating choroidal neovascularization resulting from ocular surgery or from trauma to ocular tissue and methods for their use are disclosed.... Agent: Alcon

20080234246 - Analogs of ansamycin and pharmaceutical compositions thereof: Analogs of geldanamycin (an ansamycin), pharmaceutical formulations comprising such analogs, and methods of use (e.g., treating tumors).... Agent: Leydig Voit & Mayer, Ltd

20080234247 - Heterocyclic analgesic compounds and methods of use thereof: One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates... Agent: Edwards Angell Palmer & Dodge LLP

20080234248 - Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof: e

20080234249 - Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors:

20080234250 - Heterocyclic condensed compounds useful as antidiuretic agents: The invention concerns compounds according to general formulae 1, wherein G1 is an amine. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.... Agent: Foley And Lardner LLP Suite 500

20080234251 - 8-substituted benzoazepines as toll-like receptor modulators: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.... Agent: Viksnins Harris & Padys Pllp

20080234252 - Compounds useful in therapy: o

20080234253 - Methods and compositons for stimulating neurogenesis and inhibiting neuronal degeneration: The present invention provides methods and compositions comprising compounds useful for stimulating neurogenesis. The methods and compositions comprising compounds are also useful for inhibiting neuronal degeneration. Thus, the present invention can be used in the treatment of diseases and conditions characterized by neuronal loss and reduced neurogenesis including Alzheimer's disease,... Agent: Wilmerhale/dc

20080234254 - Inhibitors of histone deacetylase: The present invention relates to a benzamide derivative comprising a head, spacer and cap group wherein the spacer includes a benzene ring substituted with an additional spacer and wherein the additional spacer is an unsaturated group.... Agent: Morgan Lewis & Bockius LLP

20080234255 - Substituted pyrimidodiazepines: e

20080234256 - Antibacterial agents: Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080234257 - Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080234258 - Dihydroxyanthraquinones and their use: e

20080234259 - Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).... Agent: Darby & Darby P.C.

20080234260 - Cysteine protease inhibitors: e

20080234261 - Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors: Novel inhibitors of Rho-kinases are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080234262 - Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors: The present invention relates to Pyrazolopyrimidine Analogs, methods of making Pyrazolopyrimidine Analogs, compositions comprising a Pyrazolopyrimidine Analog, and methods for treating mTOR-related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog. The invention also relates to treating PI3K-related disorders comprising administering to a... Agent: Wyeth Patent Law Group

20080234265 - Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors: Disclosed is the use of a combination of histone deacetylase inhibitors and epidermal growth factor receptor (EGFR) inhibitors to treat cancer.... Agent: Sheridan Ross PC

20080234264 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus,... Agent: David S. Resnick

20080234263 - Quinazoline derivatives: The invention concerns quinazoline derivatives of Formula (I) wherein each of R1, R3, R20, X1, X2, Z, W, (a) and (q) have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as... Agent: Morgan Lewis & Bockius LLP

20080234266 - Squaric acid derivatives ii: Compounds of the formula (I), in which R, X, X′ and R2, R2′, R2″, R3″, R2″″ and R7 have the meanings indicated in claim 1, are inhibitors of CHK1 CHK2 and SGK kinases and can be employed, inter alia, for the treatment of cancer.... Agent: Millen, White, Zelano & Branigan, P.C.

20080234268 - Bis-aryl amide derivatives and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as c-Met mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20080234267 - Compounds and methods of treatment: A derivative, which is useful as a ret kinase inhibitor is described herein. The described invention also includes methods of using the same in the treatment of diseases mediated by inappropriate ret kinase activity.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080234269 - N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands: d

20080234271 - Arylphenylamino- and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them: The present invention relates in part to compounds of formulas (I) and (III): and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080234270 - Pyrrole derivatives as pharmaceutical agents: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080234272 - Novel piperazines as antimalarial agents: The invention relates to novel piperazine derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, especially malaria.... Agent: Dickstein Shapiro LLP

20080234273 - Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes: e

20080234274 - Novel compounds: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080234275 - Method for treating and preventing arthritis: wherein X is selected from the group consisting of hydrogen, halo, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano and nitro; are used to treat or prevent arthritis including rheumatoid arthritis.... Agent: Connolly Bove Lodge & Hutz LLP

20080234276 - Heterocyclic triazines as hypoxic selective protein kinase inhibitors: The invention relates to novel heterocyclic triazines which are useful as hypoxic selective cytotoxic agents that mediate and/or inhibit cell proliferation, for example, through the activity of protein kinases. The invention is further related to pharmaceutical compositions containing such compounds and compositions, and to methods of treating cancer as well... Agent: Heslin Rothenberg Farley & Mesiti PC

20080234277 - Novel aza-pyridopyrimidinone derivatives: wherein R1, R2, R3, R4, R5, X1, X2, X3, Y, Z, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used in treating or preventing diseases which are modulated... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080234278 - Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions: wherein the groups R1 to R7 have the meanings given in the claims and specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, processes for preparing these compounds and... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080234279 - Ecteinascidins: The present invention is directed to several newly discovered ecteinascidin (Et) species, designated herein as Et 731, Et 815, Et 808, and Et 594. The physical properties of these compounds, their preparation and therapeutic properties are also reported.... Agent: King & Spalding

20080234280 - Use of mc4 receptor agonist compounds: This invention relates to the use of an MC4 receptor agonist compound for the manufacture of a medicament for the treatment of lower urinary tract dysfunction.... Agent: Pfizer Inc.

20080234282 - 2-(arylalkoxy)-1-phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors: Compounds of the following formula (I) wherein R1R2, n, Ar1 and A2 are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. The example compounds are 1-(2-(naphthylmethoxy)-1-phenylethyl)piperazine derivatives. The compounds are neurokinin... Agent: Pepper Hamilton LLP

20080234281 - Mitotic kinesin inhibitors: The present invention relates to N-substituted benzylic aniline derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080234283 - Glutathione peroxidase mimetics for treatment of neurodegenerative, pulmonary and inflammatory diseases: This invention relates to compositions and methods for the treatment of neurodegenerative, pulmonary and inflammatory diseases described herein with glutathione peroxidase and its mimetics.... Agent: Pearl Cohen Zedek Latzer, LLP

20080234284 - Pyrazolo[1,5-a]pyrimidin-7-yl amine derivatives as protein kinase inhibitors: i

20080234285 - Combination of organic compounds: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof and at least one PDGF receptor tyrosine kinase inhibitor.... Agent: Novartis Corporate Intellectual Property

20080234286 - Stable amorphous imatinib mesylate and production process therefor: Provided herein is a spray dried stable amorphous imatinib mesylate as a free-flowing solid and process for producing the amorphous imatinib mesylate in highly pure form.... Agent: Leydig Voit & Mayer, Ltd

20080234287 - Sulfur-containing naphthalimide derivatives: The invention discloses novel sulfur-containing naphthalimide derivatives, and the preparation and uses thereof. The conjugated plane of naphthalimide derivatives of the invention is enlarged by incorporating 5- or 6-membered heteroaromatic ring and/or introducing S heteroatom, thus increasing the anti-tumor activity of naphthalimide. The compounds of the invention displays significant inhibiting... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080234288 - Hcv inhibiting sulfonamides: for the manufacture of a medicament useful for inhibiting HCV activity in a mammal infected with HCV. The present invention also relates to the use of said sulfonamides in pharmaceutical compositions aimed to treat or combat combined HCV and HIV infections. In addition, the present invention relates to processes for... Agent: Philip S. Johnson Johnson & Johnson

20080234289 - Melanocortin receptor-specific compounds: where X, R1, R2a, R2b, R3, R4a, R4b, R5a and R5b are as defined in the specification, which compound binds with high affinity to one or more melanocortin receptors and is optionally an agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed... Agent: Morgan Lewis & Bockius LLP

20080234290 - New indole or benzimidazole derivatives as cb1 inverse agonists: and pharmaceutically acceptable salts thereof, processes for making said compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compound and pharmaceutically acceptable salts thereof, and methods of using said compounds. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080234291 - Mitratapide oral solution: The present invention concerns an oral solution comprising the MTP inhibitor mitratapide or an pharmaceutically acceptable acid addition salt thereof, a process for preparing such solutions, and their use in the treatment of MTP-related disorders such as hyperlipidemia, obesity, or type II diabetes.... Agent: Philip S. Johnson Johnson & Johnson

20080234292 - Peptidase inhibitors: The present invention relates to a series of novel compounds having the formula (I) wherein: X is NR3 or O; n is 1 or 2; A is a bicyclic carbocycle and R1 and R2 are as described herein. The compounds are useful as DPP-IV inhibitors, such as for the treatment... Agent: Myers Bigel Sibley & Sajovec

20080234293 - Tri-aryl/heteroaromatic cannabinoids and use thereof: e

20080234294 - Cxcr4 binding molecules: This invention relates to the use of a CXCR binding molecules as described in the specification, in WHIM syndrome.... Agent: Novartis Corporate Intellectual Property

20080234295 - Fungicidal mixtures based on azolopyrimidinylamines: i

20080234296 - Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists: or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder... Agent: Foley And Lardner LLP Suite 500

20080234297 - Hsp90 inhibitors containing a zinc binding moiety: The present invention relates to HSP90 inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, PC

20080234298 - Antifolate agent combinations in the treatment of cancer: Compositions and methods useful in the treatment of certain cancers. The methods include administering, to a patient receiving an antifolate anticancer agent, methoxyamine administered in an amount sufficient to enhance or increase the effect of the antifolate anticancer agent. In part, this application is based on the recognition that certain... Agent: Wilson Sonsini Goodrich & Rosati

20080234299 - Quinazolinones: Compounds of the formula (I), in which R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3, k and Y1 have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.... Agent: Baker & Daniels LLP

20080234300 - Pyrimido[5,4-c] quinoline-2, 4-diamine derivatives and methods of use thereof: The present invention relates to pyrimido[5,4-c]quinoline-2,4-diamine derivatives, compositions comprising an effective amount of a Pyrimido[5,4-c]quinoline-2,4-diamine Derivative, methods for treating or preventing a proliferative disorder, comprising administering to a subject in need thereof an effective amount of an Pyrimido[5,4-c]quinoline-2,4-diamine Derivative, methods for modulating PDK-1 activity, comprising administering to a subject in... Agent: Wyeth Patent Law Group

20080234301 - Alpha-4 integrin mediated cell adhesion inhibitors for the treatment or prevention of inflammatory diseases: The present invention relates to novel compounds of formula (I), processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell adhesion.... Agent: Birch Stewart Kolasch & Birch

20080234302 - Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium: Provided are processes for preparing amorphous rosuvastatin calcium from crystalline rosuvastatin calcium by simple precipitation processes. Also provided is a novel polymorphic form of rosuvastatin sodium, processes for preparing thereof and pharmaceutical compositions thereof.... Agent: Ranbaxy Inc.

20080234303 - Pyrimidine derivatives for the treatment of abnormal cell growth: and R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, salt thereof, wherein R1, R2, R13, A, K, L1, L2, W, X, Z1, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p and q are as defined herein. Such novel pyrimidine derivatives are useful in... Agent: Pfizer Inc

20080234304 - N3-pyridyl-thiamine and its use in cancer treatments: The invention provides methods using N3-pyridyl-thiamine compounds and pharmaceutical compositions comprising N3-pyridyl-thiamine, which are especially useful for preventing or reducing tumor growth in vivo. The invention is also directed to the benefits of reducing thiamine concentrations, e.g., by means of a thiamine reduced diet, as an effective step in a... Agent: Ropes & Gray LLP

20080234305 - Novel tetrahydropyridine derivatives: The invention relates to novel tetrahydropyridine derivatives and use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.... Agent: Thomas Hoxie Hoxie & Tso

20080234306 - N-oxides of 4,5-epoxy-morphinanium analogs: Novel N-oxides of 4,5-epoxy-morphinanium analogs are disclosed. Pharmaceutical compositions containing the N-oxides of 4,5-epoxy-morphinanium analogs and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as modulators of opioid receptors.... Agent: Kelley Drye & Warren LLP

20080234307 - Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics: This invention relates to a class of 6-amino-morphinan compounds of formula (I) which can be used as highly active analgesics. This invention also relates to their pharmaceutically acceptable salts and easily accessible derivatives (e.g. esters or amides of the amino acid derivatives), to a process for their manufacture and their... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20080234309 - Macrocyclic lactone compounds and methods for their use: i

20080234308 - Amino-aza-adamantane derivatives and methods of use: The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. Radiolabelled compounds useful for evaluating the binding affinity to α7 nicotinic acetylcholine receptors also are described.... Agent: Paul D. Yasger Abbott Laboratories

20080234310 - Methods and compositions for slowing aging: The present invention provides a pharmacological agent based on derivatives of hydrogenated pyrido (4,3-b) indoles and uses thereof. Specifically, the invention provides a geroprotector in the series of hydrogenated pyrido (4,3-b) indoles (several derivatives), which can be used for slowing aging, prolonging lifespan of an individual or cells in an... Agent: Morrison & Foerster LLP

20080234311 - Immunoassay for detection and quantification of amyloid-beta peptides: The present invention provides a method for the detection and quantification of Aβ1-40 produced in native cell types and tissues. Also provided are assays and kits to determine the effect of compounds on the production of amyloid β peptides.... Agent: Paul D. Yasger Abbott Laboratories

20080234312 - Feed or feed additive containing an alkaloid: The invention relates to a feed containing conventional feed substances, or feed additives for producing said feed. According to the invention, the feed or fed additive contains a protopine alkaloid, in particular α-allocryptopine, preferably in combination with at least one benzophenanthridine alkaloid in an active quantity as a stimulant and... Agent: K.f. Ross P.C.

20080234313 - Novel inhibitors: e

20080234314 - Fused amino pyridine as hsp90 inhibitors: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.... Agent: Elmore Patent Law Group, PC

20080234315 - M3 muscarinic acetylcholine receptor antagonists: e

20080234316 - Quinuclidine amide derivatives:

20080234317 - Methods for the improvement of memory and neurological function comprising the administration of compositions that act as inhibitors of the sodium proton (na+ /h+ ) exchanger, subtype 5 (nhe-5):

20080234318 - Chemical compounds: The present invention provides compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a target cell.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080234319 - Novel compounds 679: The invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy, wherein R1, R2, R3 and n are as defined in the specification... Agent: Fish & Richardson P.C.

20080234320 - Curcumin analogs with anti-tumor and anti-angiogenic properties: The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.... Agent: Alston & Bird LLP

20080234321 - 3,5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission: e

20080234323 - Amorphous and three crystalline forms of rimonabant hydrochloride: The present invention describes novel forms of Rimonabant hydrochloride, processes for their preparation and pharmaceutical compositions containing them. Thus, the present invention discloses three new crystalline forms designated as Form II, Form III and Form IV of Rimonabant hydrochloride and novel amorphous forms of the salt.... Agent: Nixon & Vanderhye, PC

20080234322 - Methods and apparatus for drug modeling and displaying drug models: Drug delivery models, displays, and systems may be configured to provide a clinician with readily intuitive information about the effects of one or more drugs on a subject. Interactive features may be included to provide a subject-specific model of the expected or predicted effects of one or more drugs on... Agent: Baker & Associates PLLC

20080234324 - Piperidine derivatives as gcs inhibitors: The present invention relates to novel piperidine derivatives that are useful as inhibitors of glucosylceramide synthase (GCS) for use in the treatment and prevention of diseases or disorders mediated by GCS, including cancer, infectious diseases, neuronal disorders or injury and inflammatory diseases. The invention further relates to the pharmaceutical composition... Agent: Dickstein Shapiro LLP

20080234327 - Dihydroindazole compounds useful in treating iron disorders: m, R1, R2, R3 and R4 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the... Agent: SeedIPLaw Group PLLC

20080234325 - Novel methods using pyridine derivatives: The invention provides methods of treating and preventing asthma, laryngitis, symptomatic gastroesophageal reflux disease, pregnancy-induced gastroesophageal reflux disease, noncardiac chest pains, coughing, apnea, dyspepsia, inflammatory bowel disease, irritable bowel syndrome, gastritis, stress ulcers, bleeding peptic ulcers, acute gastrointestinal bleeding, infectious enteritis, collagenous colitis, lymphocytic colitis, chronic diarrhea in immunocompromised patients,... Agent: Lahive & Cockfield, LLP/eisai Floor 30, Suite 3000

20080234326 - Novel salts of pantoprazole and (s) - pantoprazole: The invention relates to pantoprazole and (S)-pantoprazole salts and to medicaments comprising these compounds.... Agent: Nath & Associates PLLC

20080234328 - Acqueous neonicotinoid compositions for seed treatment: e

20080234329 - Carboxamide compounds and their use as calpain inhibitors:

20080234330 - Carboxamide compounds and their use as calpain inhibitors:

20080234331 - Synergistic insecticidal mixtures for the treatment of seed: The invention relates to insecticidal mixtures containing, as active substances, at least two compounds from the series of the chloronicotinyl insecticides, and to the use of these mixtures for promoting plant growth.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080234332 - Raf kinase inhibitors containing a zinc binding moiety: The present invention relates to Raf kinase inhibitors containing zinc-binding and their use in the treatment of Raf related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, PC

20080234334 - 1,4 diamino bicyclic retigabine analogues as potassium channel modulators: e

20080234333 - Novel hydroxamic acid derivative as peptide deformylase inhibitor and manufacturing method thereof: The present invention relates to the novel antibacterial compounds having potent antibacterial activity as inhibitors of peptide deformylase. This invention further relates to pharmaceutically acceptable salts thereof, to processes for their preparation, and to pharmaceutical compositions containing them as an active ingredient.... Agent: Birch Stewart Kolasch & Birch

20080234335 - Cyclohexene compounds: Compounds of formula (I) wherein A, B, Z, R1, R2a, R2b, R8, R9 and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080234336 - Synergistic imazalil combinations: The present invention relates to synergistic combinations of the antifungal agent imazalil and another antifungal agent selected from the group consisting of boscalid, cyproconazole, pyraclostrobin, triflumizole, acibenzolar-S-methyl, carpropamid, fosetyl-Al, spiroxamine, tetraconazole and zoxamide for protecting plants, fruit or seeds against phytopathogenic fungi.... Agent: Philip S. Johnson Johnson & Johnson

20080234337 - Preventive and/or remedy for hyperkalemia containing ep4 agonist: The present invention relates to a preventive and/or therapeutic agent for hyperkalemia, and a potassium excretion promoter containing EP4 agonist. Since EP4 agonist promotes potassium excretion, it is useful as a preventive and/or therapeutic agent for hyperkalemia. In addition, if selective EP4 agonist uses, it is a preventive and/or therapeutic... Agent: Sughrue Mion, PLLC

20080234338 - Neurorestoration with r(+) pramipexole: Formulations and methods of use thereof for restoring neuronal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080234339 - Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow: A method and pharmaceutical composition are disclosed for treating, ameliorating and/or preventing one or more myocardial disorders in a mammalian heart caused by a myocardial hypoxic event and/or a loss, reduction or interruption in coronary blood flow such as may happen during or after events such as a heart attack,... Agent: Dr Steven Weiss

20080234340 - Synthesis and characterization of polymorph form ii of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile: m

20080234341 - Carisoprodol and phenytoin methods: A method of using carisoprodol comprises informing a user that co-administration of carisoprodol with steady-state phenyloin results in an increase in free phenyloin blood levels, a decrease in total phenyloin blood levels, or both. In another embodiment, a method of using carisoprodol comprises informing a user that when co-administering carisoprodol... Agent: Cantor Colburn, LLP

20080234342 - Skin conditioning compositions containing compounds for mimicking the effect on skin of retinoic acid: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to a bout 50% of a combination of retinoid boosters.... Agent: Unilever Patent Group

20080234343 - Preparation with elevated content: A composition for oral use, which contains a drug compound (in particular, a hardly water soluble or water-insoluble drug compound) in an elevated amount and is excellent in the absorbability of the drug compound via the digestive tract, is produced by dispersing the drug compound in an oily base and... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080234344 - Amino acid and peptide conjugates of arylalkylic acids for cosmetic use: c

20080234345 - Method for reducing or alleviating inflammation in the digestive tract: A method is provided for reducing or alleviating inflammation or a pathological process associated therewith or secondary thereto in a subject having an inflammatory disease of the digestive tract. The method comprises administering to the subject an anti-inflammatorily effective amount of an ACE2 inhibitor.... Agent: Harness, Dickey, & Pierce, P.l.c

20080234346 - Pyrazalidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors: The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080234348 - 3-oxoindazolesquaric acid derivatives: Novel squaric acid compounds of the formula (I), in which R1, R2, R2′, R2″ and X have the meanings indicated in claim 1, are inhibitors of CHK1 CHK2 and SGK kinases and can be used for the treatment of diseases and complaints such as cancer, diabetes, obesity, metabolic syndrome (dyslipidaemia),... Agent: Millen, White, Zelano & Branigan, P.C.

20080234347 - Method for treating cb2 receptor mediated pain: v

20080234349 - Ppar active compounds: Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ.... Agent: Foley & Lardner LLP

20080234350 - Crystalline modifications to pyraclostrobin: The present invention relates to novel crystalline modifications of pyraclostrobin, to processes for their preparation and to the use of the novel modifications for preparing crop protection compositions.... Agent: Brinks, Hofer, Gilson & Lione

20080234351 - Combination methods for preserving visual acuity: The present invention relates to a method for preserving the vision of a patient suffering from diabetic retinopathy which comprises administering to said patient an effective amount of ruboxistaurin or a pharmaceutical salt thereof wherein said administration is in conjunction with focal or grid laser photocoagulation therapy.... Agent: Eli Lilly & Company

20080234352 - Controlled release solid dispersions: A controlled release pharmaceutical composition for oral use comprising a solid dispersion of i) at least one therapeutically, prophylactically and/or diagnostically active substance, which at least partially is in an amorphous form, ii) a pharmaceutically acceptable polymer that has plasticizing properties, and iii) optionally a stabilizing agent, the at least... Agent: Foley And Lardner LLP Suite 500

20080234353 - Formulations of ramipril: The present invention relates to stable tablet formulations of ramipril, optionally in combination with a diuretic.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080234354 - Methods and compositions for controlling body weight and appetite: The present invention provides novel compositions and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound. The invention also provides novel compositions and methods for treating or preventing disorders related to or complicated by excessive body weight or obesity, including coronary heart disease,... Agent: Jeffrey J. King, Esq. Black Lowe & Graham PLLC

20080234355 - Dna methyl transferase inhibitors containing a zinc binding moiety: The present invention relates to inhibitors of DNMT containing zinc moiety derivatives that have enhanced or unique properties as inhibitors of DNA methyl transferases (DNMT) and their use in the treatment of DNMT related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, PC

20080234356 - 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives: e

20080234357 - Indole derivatives substituted with long-chain alcohols and medicaments containing them: wherein R1, R2, R3 and R4 each independently represent a hydrogen atom, a methyl group, an acetyl group, or a hydroxyl group, and n represents a number from 0 to 20; and a medicinal composition comprising the same. The indole long-chain alcohol (I) exhibits an excellent nerve growth promoting effect,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080234358 - Naphthalene derivatives: e

20080234359 - Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof: Solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.... Agent: Jones Day

20080234360 - Attractants for insects such as flies: l

20080234361 - Pharmaceutical compositions, methods of formulation thereof and methods of use thereof: A pharmaceutical composition including a physiologically effective amount of a mixture of conjugated fatty acid(s) and polyphenol(s) is disclosed. Methods of formulation are further disclosed. Trienoic acids such as punicic acid are employed in exceptionally preferred embodiments of the invention. The invention has utility in management/treatment of a wide range... Agent: Dr. Mark M. Friedman C/o Bill Polkinghorn - Discovery Dispatch

20080234363 - Antitumoral compounds: Compounds of general formula (I), wherein R1, R2, R3, R4, R5, R6 and Y are as defined, and X group is O, S(O)m or NR; are of use in the treatment of cancer.... Agent: King & Spalding

20080234364 - Composition and method for treating diabetes and metabolic disorders: A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.... Agent: Renner Otto Boisselle & Sklar, LLP

20080234362 - Treatment for asthma and arthritis and other inflammatory diseases: A synergistic effect is obtained in the treatment of combined omega-3 series polyunsaturated fatty acids and flavonoids in the treatment of asthma, chronic obstructive pulmonary disease, rheumatoid and osteoarthritis, and other inflammatory conditions. The fatty acids are extracted from the New Zealand Green Lipped Mussel Perna canaliculus.... Agent: Conley Rose, P.C. David A. Rose

20080234365 - Non-nuclear effects of thyroid hormone: Truncated thyroid hormone receptors ΔTRα1 and ΔTRα2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of ΔTRα1 and ΔTRα2. The invention is useful for the... Agent: Fish & Richardson PC

20080234367 - Methods for treating obesity employing an sglt2 inhibitor and compositions thereof: Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP Bristol-myers Squibb

20080234366 - Pharmaceutical formulation containing an sglt2 inhibitor: t

20080234368 - Therapeutic compositions and methods of use: Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.... Agent: Fulbright & Jaworski L.L.P.

20080234369 - 3,4,5,4' - tetramethoxyl- alpha,beta-diphenylethane -3' -0- sodiumsulphate and its use: This invention relates to a compound of formula (I), 3,4,5,4′-tetramethoxyl-α,β-diphenylethane-3′-O-sodium sulphate, and its use in the preparation of antineoplastic pharmaceutical.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080234370 - Calcilytic compounds: Novel calcilytic compounds and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080234371 - Non-hygroscopic l-carnitine salts: wherein Z is acetate, propionate, or butyrate. In addition, processes for the preparation of these compounds are provided, together with the use of these compounds as a source of both L-carnitine and the calcium ion in nutrition or as a pharmaceutical active ingredient having therapeutic pharmacological activity.... Agent: Kent Barta S.c.

20080234372 - Creatine salt with enhanced nutritional and therapeutic efficacy and compositions containing same: The novel salt creatine glycinate and compositions (dietary supplements, energy drinks, and dietetic or pharmaceutical products containing the same are described.... Agent: Iovate Health Science Research Inc.

20080234373 - Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients: Is described the use of propionyl L-carnitine, or a pharmaceutical salt thereof, for preparing a medicament for the prevention and/or treatment of left ventricular hypertrophy in ESRD or dialysed patients.... Agent: Lucas & Mercanti, LLP

20080234374 - Compositions and method for removing hair: The invention encompasses a composition for hair removal comprising at least one organic hair follicle penetrating agent and at least one enzyme inhibitor for the purpose of achieving permanent hair follicle inactivation, and methods for hair removal using the same.... Agent: Kenyon & Kenyon LLP

20080234375 - Process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product: The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080234376 - Emulsion composition comprising prostaglandin e1: An emulsion composition includes prostaglandin E1 (PGE1), a phospholipid with a high purity and a non-proton-providing surfactant that improves stability of PGE1. Embodiments of the emulsion composition include an effective amount of PGE1, about 1% to about 30% (w/w) of a pharmaceutically acceptable oil as an oil base based on... Agent: Panitch Schwarze Belisario & Nadel LLP

20080234377 - Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions: Disclosed are compositions and methods for treating or preventing dementia and pre-dementia-related conditions and/or symptoms or characteristics of such conditions.... Agent: Sheridan Ross P.C.

20080234378 - Methods for the preparation and formulation of l-carnitine valproate salts: The present invention relates to methods for preparing an L-carnitine valproate salt and administering this compound to a subject in need of treatment with valproate. Pharmaceutical compositions are also provided that are useful therapies for the treatment of neurological, immunological, and viral-mediated disorders in warm-blooded mammals.... Agent: Kent Barta S.c.

20080234379 - Therapeutic methods employing nitric oxide precursors: Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080234380 - Compositions and method for treatment of chronic inflammatory diseases: This invention defines novel compositions that can be used for clinical treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, namely aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clinical disorders addressed herein. Such carbonyl... Agent: Howard K. Shapiro, Ph.d.

20080234381 - Novel trifluoromethoxy-substituted aryl anilides: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or disorders associated therewith.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080234382 - Methods for the preparation, formulation and use of lithium valproate: The present invention relates to methods for preparing lithium valproate and administering this compound to a subject in need of treatment with lithium and/or valproate. Pharmaceutical compositions are also provided that are useful therapies for the treatment of neurological, immunological, and viral-mediated disorders in warm-blooded mammals.... Agent: Kent Barta S.c.

20080234383 - Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same: This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receotor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies,... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080234384 - Biaryl and biheteroaryl compounds useful in treating iron disorders: m, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the... Agent: SeedIPLaw Group PLLC

20080234385 - Method for inhibiting tnf-alpha: The present invention encompasses methods for inhibiting TNF-alpha expression with N-substituted dopamine derivatives. In this method a cell is administered a pharmaceutically effective amount of N-acetyl dopamine derivatives or N-alkyldopamine derivatives and a pharmaceutically acceptable carrier for treating a cell, preferably in an animal or human suffering from overexpression or... Agent: David S. Resnick

20080234386 - Methods and compositions for controlling pests: The present invention is directed to pest-controlling compositions comprising as active ingredients one or more β-diones, particularly β-diketones and β-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The... Agent: Knobbe Martens Olson & Bear LLP

20080234387 - Active substance mixtures comprising opp and amines, microbicidal agents: The invention relates to novel biocidal active substance mixtures containing o-phenylphenol and amines, methods for the production thereof the use thereof for protecting technical materials and products from being infested and destroyed by microorganisms, and microbicidal agents based on said novel mixtures.... Agent: Lanxess Corporation

20080234388 - Integrin modulators and methods for their use: 1,5-Dithiaocta-2,7-diene-5-oxide-1-yl (DODOyl) compounds and derivatives thereof, referred to collectively as DODOyl-derived compounds (DDCs), and chiral enantiomers and derivatives thereof, are described, which are integrin modulators that modulate integrin-mediated functions and/or processes. Pharmaceutical compositions containing integrin modulators and chiral enantiomers thereof, and methods for using integrin modulators and chiral enantiomers thereof... Agent: Brinks Hofer Gilson & Lione

20080234389 - Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics: The present invention provides therapeutic formulations, including therapeutic emulsions and nanoemulsions, and related methods for the delivery of fluorinated therapeutic compounds, including an important class of low boiling point perfluorinated and/or perhalogenated volatile anesthetics. Emulsion-based fluorinated volatile anesthetic formulations compatible with intravenous administration are provided that are capable of delivering... Agent: Greenlee Winner And Sullivan P C

20080234390 - Skin pore minimizers and skin elasticity improvers: The skin pore tighteners according to the present invention have excellent effect in tightening skin pores and rendering them less conspicuous, while the skin elasticity improvers and skin tighteners according to the present invention have superb effect in preventing and lessening skin wrinkles and sagging. Accordingly, they are useful as... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080234391 - Synthesis of reversible shell crosslinked nanostructures: In one aspect, the present invention is directed to a thermally responsive AB diblock copolymer prepared by RAFT polymerization wherein the diblock copolymer comprises poly(N-(3-aminopropyl)methacrylamide hydrochloride)-block-(N-isopropylacrylamide). Nanostructures of the thermally responsive diblock copolymer are formed by molecularly dissolving the diblock copolymer in aqueous solution at room temperature; and increasing the... Agent: Howrey LLP-hn

20080234392 - Trehalose fatty acid ester composition: Provided is a pigment dispersant having excellent pigment dispersibility thus allowing a larger amount of pigments to be blended in various cosmetics, and capability of imparting good sense of use, make-up lasting, odor, and stability over time to the cosmetic. A trehalose fatty acid ester composition prepared by esterifying trehalose... Agent: Wood, Herron & Evans, LLP

20080234393 - Compounds and methods for detection of carcinomas and their precursor lesions: The present invention relates to compounds and methods for detection and treatment of carcinomas and their precursor lesions. The invention provides DNase nucleic acids and polypeptides useful for the detection and treatment of carcinomas and their precursor lesions. The invention is more specifically related to a method for detection of... Agent: Akerman Senterfitt

20080227687 - Composition and method for cancer treatment using targeted single-walled carbon nanotubes: The present invention is a method for detecting and destroying cancer tumors. The method is based on the concept of associating a linking protein or linking peptide such as, but not limited to, annexin V or other annexins to single-walled carbon nanotubes (SWNT) to form a protein-SWNT complex. Said linking... Agent: Dunlap Codding, P.C.

20080227683 - Compounds having antitumor activity: Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances.... Agent: Nixon & Vanderhye, PC

20080227689 - Dampening humoral and innate immunity by inhibition of ppgalnact-1: The invention provides methods and compositions for treating pathogenic immune and inflammatory disorders through inhibition of polypeptide GalNAc transferase 1 (ppGalNAcT-1) transferase activity.... Agent: Townsend And Townsend And Crew, LLP

20080227688 - Inhibition of viral replication: The present invention provides inhibitors of viral replication, and methods related thereto. In general, such compounds can be classified as peptidyl fluoromethylketones (PFMKs). The PFMK compounds may be used to partially or completely inhibit viral infection. In certain embodiments, Z-FA-FMK may be used to inhibit replication of a reovirus, such... Agent: Fulbright & Jaworski L.L.P.

20080227685 - Methods and compositions for the treatment of gastrointestinal disorders: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic... Agent: Fish & Richardson PC

20080227686 - Novel peptides that promote lipid efflux: Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080227684 - Small molecule inhibitors of pdz interactions: The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided.... Agent: Fulbright & Jaworski L.L.P.

20080227690 - Particles for inhalation having rapid release properties: The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method... Agent: Elmore Patent Law Group, PC

20080227691 - Blood coagulation fviii analogues: The invention is related to a FVIII analogue which has a circulation time in the blood stream before activation of at least about two times of that of native FVIII and a week after injection to a patient retains at least about 5% of the FVIII activity compared to the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080227692 - Compositions and methods for treating ophthalmic disorders: The present invention relates to compositions and methods for treating and/or preventing ocular disorders, diseases or conditions and compositions and methods for treating or preventing ophthalmic conditions and disorders in a subject in need thereof.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080227693 - Cyclic peptide isolation by spray drying: Methods for isolation of a synthetic cyclic peptide by spray drying, including spray drying at elevated temperatures, products made by the methods, and synthetic cyclic peptides preparations with defined characteristics, including an essentially amorphous acid addition salt of Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH in the form of a fine powder with a particle diameter... Agent: Palatin Technologies, Inc.

20080227701 - Antiangiogenic polypeptides and methods for inhibiting angiogenesis: Conjugated kringle protein fragments are disclosed as compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.... Agent: Dykema Gossett PLLC

20080227705 - Apoptosis-inducing agent and method for inducing apoptosis: An object of the present invention is to provide a novel means for stably and surely inducing cell apoptosis using the c-myc gene as a target. The present invention relates to an apoptosis-inducing agent containing a protein that interacts with an FBP protein or a polynucleotide encoding the protein as... Agent: Sughrue Mion, PLLC

20080227697 - Bacterial protein phosphoinositide probes and effectors: Methods for detecting and quantifying phosphoinositide lipids in a sample are provided, together with novel SidC- and SdcA-derived polypeptide fragments, or fusion proteins comprising such fragments that may be effectively employed as PI(4)P probes in biochemical and cell biological assays. Applications of the disclosed probes include: (i) detection and quantification... Agent: Speckman Law Group PLLC

20080227707 - Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20: Three novel low molecular weight (LMW) polypeptide fragments of a proteolipid protein human PLP/DM20 are designated PIRP-M, PIRP-L and PIRP-J, and are growth factors for oligodendrocytes with anti-apoptotic activity. They are encoded by mRNA from an IRES. Fusion polypeptides of such a LMW polypeptide, DNA encoding the LMW polypeptide and... Agent: Harness, Dickey & Pierce, P.L.C

20080227706 - Bvh-a2 and bvh-a3 antigens of group b streptococcus: Group B Streptococcus polypeptides and polynucleotides encoding them are disclosed. Said polypeptides may be useful for the prophylaxis, diagnostic and/or therapy of streptococcal infection in mammals. Also disclosed are recombinant methods of producing the polypeptide antigens as well as diagnostic assays for detecting streptococcal infections, particularly GBS.... Agent: Seed Intellectual Property Law Group PLLC

20080227700 - Compositions and methods for treatment of protein misfolding and protein aggregation diseases: Small molecular weight molecules are provided including, but not limited to, peptides, peptide analogs and peptide mimetics that stabilize and prevent the aggregation of abnormally folded and compromised proteins. Methods for treatment of disease are provided utilizing the peptides, peptide analogs or peptide mimetics, or utilizing nucleic acids encoding the... Agent: Woodcock Washburn LLP

20080227711 - Cxc-chemokine antagonists: A novel CXC-chemokine binding protein is cloned from the salivary glands of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immuno-modulatory compounds and in the treatment or prevention of CXC-chemokine-related diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080227704 - Cxcl13 binding proteins: The present invention encompasses CXCL13 binding proteins. Specifically, the invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for CXCL13 and CXCL13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion... Agent: Abbott Bioresearch

20080227709 - Gene expression in peripheral blood mononuclear cells from children with diabetes: The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-1β (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention... Agent: Chalker Flores, LLP

20080227714 - Human tumor necrosis factor tr18 and methods based thereon: The present invention relates to TR18 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR18 protein. TR18 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR18... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080227715 - Liquid composition of factor vii polypeptides: The invention concerns a liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 9.0; (iii) an agent selected from the group consisting of: a calcium salt, a magnesium salt, or a mixture thereof; wherein... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080227712 - Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific... Agent: Robins & Pasternak

20080227708 - Methods of attenuating prostate tumor growth by insulin-like growth factor binding protein-3 (igfbp-3): Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) inhibits cell growth and promotes apoptosis by sequestering free Insulin-like Growth Factor (IGF), and also demonstrates IGF-independent, pro-apoptotic, anti-proliferative effects on prostate cancer cells. Prostate tumor size was significantly attenuated in transgenic mice over-expressing IGFBP-3 compared with wild-type mice. In addition, a marked reduction... Agent: St. Onge Steward Johnston & Reens, LLC

20080227694 - Novel interaction between proteins, and therapeutic agent for disuse muscular atrophy or method associated with disuse muscular atrophy taking advantage of novel interaction: [Solution Means] It has been found that there is an interaction between proteins between proteasome and ZNF216 (or AWP1). It has also been found that there is an interaction between proteins between a polyubiquitin chain and ZNF216 (or AWP1). By utilizing this novel interaction between the proteins, a therapeutic agent... Agent: Roberts Mlotkowski Safran & Cole, P.C.

20080227703 - Novel neurotrophic factors: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080227698 - Oligopeptides for treatment of osteoporosis and other bone diseases and methods thereof: Oligopeptides which can be used to treat bone disease such as osteoporosis are disclosed. Further disclosed are methods of treating bone disease such as osteoporosis. These methods include administration of a polypeptide encoded by the Mesd gene, or an oligopeptide comprising a contiguous subsequence of a Mesd polypeptide.... Agent: Sonnenschein Nath & Rosenthal LLP

20080227713 - Oxidized human bnp: The invention disclosed herein relates to oxidized forms of brain natriuretic peptide (BNP), particularly human BNP (hBNP). The disclosed invention relates to oxidized forms of B-type natriuretic peptide (BNP), which is useful as a marker for cardiovascular disease... Agent: Philip S. Johnson Johnson & Johnson

20080227702 - Repair of larynx, trachea, and other fibrocartilaginous tissues: Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues... Agent: Ropes & Gray LLP

20080227695 - Sfrp expression enhancing agent: Tumor formation and reduced transcription of both sFRP1 gene and sFRP2 gene were found in Dlg gene knock-out mice, and thereby the following has been provided: an agent for enhancing the expression and/or function of sFRP, containing a compound having an effect of enhancing the expression and/or function of Dlg;... Agent: Kilyk & Bowersox, P.l.l.c.

20080227696 - Single branch heparin-binding growth factor analogs: A heparin-binding growth factor (HBGF) analog having two substantially similar sequences (homodimeric sequences) branched from a single amino acid residue, where the sequences are analogs of a particular HBGF that binds to a heparin-binding growth factor receptor (HBGFR), or alternatively that bind to a HBGFR without being an analog of... Agent: Peacock Myers, P.C.

20080227699 - Therapeutic agent for neurodegenerative diseases: The present invention relates to a pharmaceutical composition for the treatment and/or prevention of a neurodegenerative disease, comprising the following polypeptide shown in any of (a) to (c): (a) a polypeptide comprising the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1); (b) a polypeptide comprising an amino acid... Agent: Birch Stewart Kolasch & Birch

20080227710 - Use of conjugates of doxorubicin with lactosaminated albumin: The present invention refers to the use of a conjugate of doxorubicin with lactosaminated human albumin for the preparation of a pharmaceutical composition useful in the treatment of hepatocellular carcinomas (HCCs) which do not express the asialoglycoprotein receptor (ASGP-R). The conjugate which was previously prepared and studied only for the... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20080227717 - Potent compstatin analogs: Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080227716 - Use of peptides for protecting skin from hair-treatment agents: The present invention relates to the use of short-chain peptides for the protection of the skin from hair-treatment agents, and particularly for the protection of the scalp from dyes or colorants.... Agent: Michael J Striker Striker Striker & Stenby

20080227718 - Prevention and treatment of amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease.... Agent: Townsend And Townsend And Crew, LLP

20080227719 - Prevention and treatment of amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease.... Agent: Townsend And Townsend And Crew, LLP

20080227720 - Tumor cytotoxicity induced by modulators of the cxcr4 receptor: The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences... Agent: Glenna Hendricks

20080227723 - Peptides for preventing or treating liver damage: The application of a peptide having sequence of formula I or its derivant in preparing the medicine for preventing or treating liver damage, especially liver damage and hepatitis C is disclosed, Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (formula I) wherein, Xaa1 is deletion, Ala,Gly,Val,Leu or Ile, Xaa2 is Thr or Ser, Xaa3 is Tyr, Phe... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080227721 - Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders: A pharmaceutical composition comprising a peptide consisting of Arg-Val-Ala-Val-Ile-Met-Gly-amide-having at least one D-amino acid.... Agent: Proteotech, Inc.

20080227722 - Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization: Drug delivery is targeted to new opioid receptors using receptor-mediated internalization. Dermorphin was successfully conjugated to DSPE-PEG3400 without affecting the affinity to its receptor. The synthesized conjugate was inserted into preformed sterically stabilized liposomes to obtain dermorphin-grafted SSL. DSPE-PEG34Qo-dermorphin and dermorphin-SSL retained their affinity and selectivity for MOR. Moreover, dermorphin-SSL... Agent: Licata & Tyrrell P.C.

20080227724 - Anti-inflammatory agents: u

20080227725 - Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes: The present invention relates to the use of at least one peptide, with the sequence (AA)n-Arg-Gly-Ser-(AA)n, where (AA) is any amino acid or one of its derivatives, and N is an integer between 0 and 3, as an active ingredient, in or for the preparation of a cosmetic and/or dermatological... Agent: Young & Thompson

20080227726 - Methods and apparatus for creating particle derivatives of hdl with reduced lipid content: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080227727 - Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors: Disclosed are methods and compositions useful in identifying an E3 ubiquitin ligase inhibitor and modulating cell growth, comprising contacting a cell with an effective amount of an inhibitor of an E3 ubiquitin ligase, and contacting the cell with an effective amount of a topoisomerase inhibitor, wherein the treatment with the... Agent: Cooper & Dunham, LLP

20080227729 - Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds: Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ cyclic AGPs for selectively stimulating immune responses in animals and plants.... Agent: Townsend And Townsend And Crew, LLP

20080227728 - Therapeutic agent for the treatment of a condition associated with peripheral vascular disease: The present invention comprises the use of oleuropein in the preventive and/or therapeutic treatment of a condition associated to the peripheral vascular disease, particularly to venous insufficiency.... Agent: Berenbaum, Weinshienk & Eason, P.c

20080227730 - 9a-carbamoyl and thiocarbamoyl azalides with antimalarial activity: 9a-carbamoyl and thiocarbamoyl azalides A and their pharmaceutically acceptable derivatives are useful for treatment and prevention of malaria.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080227731 - Biphenyl inhibitors of carbonyl reductase: Compositions of matter and methods of treating cancer patients may prevent or limit cardiotoxicity during or after chemotherapy, and/or may prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Thus, the compositions and methods may be used to... Agent: Pedersen & Company, PLLC

20080227732 - Treatment and control of severe infections including cystic fibrosis: The present invention provides a pharmaceutical composition comprising antibiotic combination products for delivering two or more different antibiotics simultaneously, wherein the two different antibiotics comprise one which consisting of concentration dependent killing and the other concentration independent killing or time dependant killing activity. The invention has been worked out utilizing... Agent: Amin Hallihan, LLC

20080227735 - Aptamers selected from live tumor cells and the use thereof: The invention relates to aptamers selected from live tumor cells and to the use thereof for diagnosis and treatment of certain cancers and other pathologies.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080227744 - Benzofuran derived hiv protease inhibitors: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.... Agent: Proskauer Rose LLP

20080227743 - Compositions and kits for treating influenza: Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.... Agent: Adamas Pharmaceuticals, Inc.

20080227738 - Compositions and methods for cell dedifferentiation and tissue regeneration: The present invention provides methods and compositions to dedifferentiate a cell. The ability of the methods and compositions of the present invention to promote the dedifferentiation of differentiated cells, including terminally differentiated cells, can be used to promote regeneration of tissues and organs in vivo. The ability of the methods... Agent: Ropes & Gray LLP

20080227740 - Compositions and methods for elimination of unwanted cells: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium... Agent: Fish & Richardson P.C.

20080227739 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080227733 - Method for treating and preventing ischemia-reperfusion injury using rna interfering agent: The present invention is based, at least in part, on the discovery of methods useful in the modulation, e.g., inhibition, of gene expression or protein activity, e.g., apoptosis-related gene expression, e.g., Fas gene expression or cytokine expression, e.g., proinflammatory cytokine expression. In particular, the present invention is based on novel... Agent: David S. Resnick

20080227745 - Methods and compositions for soluble cpg15: Disclosed herein are compositions of soluble CPG15 and methods for treating conditions of excessive cell death, such as neurological conditions, using such compositions. Compounds that inhibit the activity of soluble CPG15 are also disclosed herein for the treatment of conditions of undesirable cell survival, such as cancer.... Agent: Clark & Elbing LLP

20080227742 - Photocleavable oligonucleotide and uses thereof: This invention relates to methods and compositions of oligonucleotide constructs having a photocleavable linker. Specifically, provided herein are methods and compositions utilizing a photocleavable linker, which when exposed to light modulates the expression of genes.... Agent: Pearl Cohen Zedek Latzer, LLP

20080227736 - Targeting pseudotyped retroviral vectors: The present invention relates to retroviral vectors, particularly lentiviral vectors, pseudotyped with Sindbis envelope and targeted to specific cell types via a targeting moiety linked to the envelope.... Agent: Townsend And Townsend And Crew, LLP

20080227737 - Type 2 diabetes mellitus genes: Methods and compositions related to novel genes associated with type 2 diabetes mellitus.... Agent: Fish & Richardson PC

20080227741 - Zap-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (cll/sll): It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA... Agent: Klarquist Sparkman, LLP

20080227746 - Methods and compositions for treatment of excess nitric oxide or cyanide toxicity: Methods for treating disease states in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide are provided. Methods for alleviating the symptoms of a disease state in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide... Agent: Woodcock Washburn LLP

20080227749 - Carrageenan-based formulations and associated methods of use: A method is provided for treating a female individual who suffers from or is prone to dyspareunia. The method involves vaginal and/or vulvar administration of a formulation comprising a therapeutically effective amount of a carrageenan and a pharmaceutically acceptable aqueous carrier. In addition, a carrageenan-based formulation is provided as a... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080227747 - Composition and methods for treating or preventing degenerative joint and cardiovascular conditions: A therapeutic composition and methods for the treatment and prevention of a degenerative joint disorder and/or a cardiovascular disease comprising polycosanols, glucosamine and chondroitin are disclosed.... Agent: Brinks, Hofer, Gilson & Lione

20080227750 - Compositions and methods for regulating receptor clustering: The invention relates to isolated complexes comprising one or more galectin associated with a Mgat5 modified glycan or polylactosamine modified glycan, and isolated lectin-Mgt5 modified glycan lattice comprising an array of mulitvalent interactions among lectins, Mgat5 modified glycans, polylactosamine modified glycans, and/or glycoproteins. Methods for evaluating a test compound for... Agent: Howson And Howson

20080227748 - Medicament made from laminarine or oligolaminarines for treatment of septicemia and septic shock: The invention relates Lo the use of laminarine, preferably in the soluble form thereof or an oligolaminarine, for the production of a medicament for treatment of septicemia and septic shock.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080227751 - Method and agent for the prevention, inhibition and treatment of sepsis: The invention relates to the use of Asialo-Gm1 (Agm1,) and/or GM gangliosides, and substances which simulate the carbohydrate part of said gangliosides in terms of binding to anti-AGm1 antibodies and/or anti-Gm1 antibodies, for producing an agent which blocks or binds to anti-AGm1 antibodies and/or anti-Gm1 antibodies which bind to natural... Agent: Heslin Rothenberg Farley & Mesiti PC

20080227752 - Methods to inhibit histone acetyltransferase using glycosaminoglycans: The present invention is directed to methods for inhibition of histone acetyltransferases using glycosaminoglycans. The invention is further directed to methods for treating disorders associated with hyperacetylation by administration of glycosaminoglycans to a patient in need thereof. In one preferred embodiment, the glycosaminoglycan is a heparin or heparan sulfate oligosaccharide.... Agent: Ronald I. Eisenstein

20080227753 - Nano-sized bagasse fiber: A new composition of nanosized bagasse fibers has been made by a method which reduces the sugarcane bagasse fibers to nano-sized particles while retaining the natural components of the bagasse. The resulting bagasse particles were shown to be effective as a nutritional supplement in a mouse model to aid in... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20080227754 - Prodrugs of phosphonate nucleotide analogues: n

20080227755 - Method of administering bisphosphonates: Bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, can be used with satisfactory results for treatment of RA by intermittent administration, wherein the periods between bisphosphonate administrations are from about 2 months up to about 4 months, e.g. once every 3 months.... Agent: Novartis Corporate Intellectual Property

20080227734 - Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis, and treatment: A novel mutant form of lrp5 and lrp6 genes, the mutant LRP5 and LRP6 receptor proteins expressed therefrom, and a cell line which expresses the mutant LRP5 and/or LRP6 receptor proteins. Methods of diagnosing, prognosing and treating LRP5 related diseases, specifically hyperthyroidism and parathyroid tumors, and kits suitable for rapid... Agent: Dinsmore & Shohl, LLP

20080227756 - Use of bisphosphonates for the treatment of osteogenesis imperfecta: This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average.±.1 DS). Then the administration of the bisphosphonate preparation is... Agent: Patent Central LLC Stephan A. Pendorf

20080227757 - Formulation for dermal application: The present invention relates to formulations on an aqueous basis with polyetherpolyol, dimethyl isosorbide, lipid and alcohol content suitable for penetration reinforcement of pharmaceutical active ingredients in the dermal application. The pharmaceutical active ingredients can be amphiphilic, zwitterionic, strongly polar or lipophilic. A preferred active ingredient is 5-aminolevulinic acid.... Agent: Collard & Roe, P.C.

20080227758 - Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors: The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic... Agent: Merck And Co., Inc

20080227759 - Topical composition: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.... Agent: Dykema Gossett PLLC

20080227760 - Method of extracting ginsengnoside rg2m, pharmaceutical composition including ginsengnoside rg2, and uses thereof: The present invention provides a method of extracting ginsenoside Rg2, which is applied to mass production. The method of the present invention employs gradient salting-out instead of conventional silica gel chromatography, and therefore enables convenient performance and mass production of ginsenoside Rg2. Provided are also a pharmaceutical composition comprising ginsenoside... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080227762 - Lupeol anti-tumor agent and uses thereof: The present invention provides a method of treating melanoma comprising parenterally administering to a human a therapeutically effective amount of a parenteral composition of a Lupeol-derived anti-tumor compound.... Agent: Quarles & Brady LLP

20080227761 - Method of treating immune pathologies with low dose estrogen: The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and... Agent: Klarquist Sparkman, LLP

20080227763 - Topical hormonal composition with systemic action: It relates more particularly to a topical hormonal composition with systemic action for the correction of progesterone deficiency in premenopausal women and for hormone replacement in menopausal women, characterized in that it contains, as the active principle, a progestogen derived from 19-nor progesterone, a vehicle permitting systemic passage of the... Agent: Charles A. Muserlian C/o Hedman And Costigan

20080227764 - Use of pregnane-diones or diols as neuropathic analgesic agents: The present invention relates to the use of pregnanes in inducing analgesia, preferably without overt sedation, in a mammal in response to neuropathic pain, and compositions and kits therefore.... Agent: Knobbe Martens Olson & Bear LLP

20080227765 - Cytotoxic depsipeptides: Compounds of general formula (1) wherein R1, R2, R3 are as defined and R4 groups are each independently selected from NR2, O and S; are of use in treatment of cancers.... Agent: Fish & Richardson PC

20080227766 - Synergistic, silver-containing biocide composition: A biocidal composition comprising a combination of at least two biocidal components, in which 1,2-benzisothiazolin-3-one and/or N-methyl-1,2-benzisothiazolin-3-one and/or N-methyl-1,2-benzisothiazolin-3-one are used as one component and silver in the form of, for example, organic or inorganic silver salts, colloidal or nanoparticulate silver or silver oxide is used as the other component,... Agent: Nixon Peabody, LLP

20080227767 - Methods and compounds for inhibiting amyloid deposits: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080227768 - Crystal of 1-methylcarbapenem compound: Among crystalline forms of compound (I), a 1-methylcarbapenem compound represented by the formula (I) in a crystalline form that shows main peaks in the X-ray powder diffraction pattern obtained with copper Kα irradiation.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080227769 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080227770 - Benzoxazepine compound: wherein ring A and ring B each represent an optionally substituted benzene ring; ring C represents an optionally further substituted aromatic ring; R1 represents a lower alkyl group optionally substituted with an optionally substituted hydroxyl group; X1a represents a bond or optionally substituted lower alkylene; X1b represents a bond or... Agent: Edwards Angell Palmer & Dodge LLP

20080227771 - Delta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it: e

20080227773 - Diazabicyclic aryl derivatives as cholinergic receptor modulators: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse... Agent: Birch Stewart Kolasch & Birch

20080227772 - Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of... Agent: Birch Stewart Kolasch & Birch

20080227774 - 5,5-disubstituted-indolizinone compounds: The invention is directed to 5,5-disubstituted-indolizinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Connolly Bove Lodge & Hutz LLP

20080227775 - Quinoline derivatives as antibacterial agents: R3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; R4 is hydrogen, alkyl or benzyl; R5 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R5 radicals may be taken together to form together with the phenyl ring to which they are attached... Agent: Philip S. Johnson Johnson & Johnson

20080227776 - Inhibitors of hemeprotein-catalyzed lipid peroxidation: Methods and compounds for the treatment or prevention of oxidative damage in a mammalian subject. The treatment and/or prevention may be on inhibiting heme-induced lipid peroxidation. Also discloses are methods and compounds for treating or preventing isoprostane-mediated tissue damage.... Agent: Stites & Harbison PLLC

20080227777 - Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1: t

20080227779 - Heterocyclic compounds and methods of use:

20080227778 - Isoquinolinone potassium channel inhibitors: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20080227781 - Imidazole compounds for the treatment of neurodegenerative disorders: wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising... Agent: Pfizer Inc Steve T. Zelson

20080227780 - Soluble epoxide hydrolase inhibitors: Disclosed are urea compounds, stereoisomer, or pharmaceutical acceptable salt thereof, and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases,... Agent: Foley & Lardner LLP

20080227782 - Pyrimidine amide compounds as pgds inhibitors: s

20080227783 - 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors: The invention provides 5-substituted thiazol-2-yl amino compounds of Formula (I): pharmaceutical compositions comprising such compounds and the use of such compounds for the treatment or prevention of diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Ab 1, Aurora-A, Ber-Ab1,... Agent: Genomics Institute Of The Novartis Research Foundation

20080227784 - N-(3,4-disubstituted phenyl) salicylamide derivatives: wherein R1, R2, R3 and R4 represent hydrogen atom, a halogen atom, cyano group, nitro group, a C1-4 alkyl group, a halogenated C1-4 alkyl group or a C1-4 alkoxy group, R5 represents a halogen atom, cyano group, a C1-4 alkyl group, a halogenated C1-4 alkyl group or a C1-4 alkoxy... Agent: Greenblum & Bernstein, P.L.C

20080227785 - 2,4,6-triamino-1,3,5-triazine derivative: e

20080227789 - Diaminothiazoles useful as axl inhibitors: Diaminothiazoles and pharmaceutical compositions containing them are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the diaminothiazoles in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20080227786 - Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor: Novel crystalline salts of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-&agr; amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof... Agent: Merck And Co., Inc

20080227787 - Use of new lipoxygenase inhibitors: There is provided a use of a compound of formula (I), wherein R1, R2, R3 and R4 have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase)... Agent: Nixon & Vanderhye, PC

20080227788 - Imidazopyrazine tyrosine kinase inhibitors: e

20080227790 - Pyridazinone derivatives and their use as pde4 inhibitors:

20080227791 - Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists: The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect... Agent: Woodcock Washburn LLP

20080227792 - 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl esters: Novel compounds of formula (I), pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080227793 - Benzimidazole and pyridylimidazole derivatives: This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080227794 - Metabotropic glutamate-receptor-potentiating isoindolones: i

20080227795 - 6(2-chloro-5-halophenyl)triazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds: The invention relates to substituted triazolopyrimidines of formula (I), with the substituents as follows: R1, R2=H, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkenyl, haloalkenyl, cycloalkenyl, halocycloalkenyl, alkinyl, haloalkinyl, phenyl, naphthyl, or a five- or six-membered saturated, partially unsaturated or aromatic heterocycle, comprising one to four heteroatoms of the group O, N or... Agent: Birch Stewart Kolasch & Birch

20080227796 - 7-amino-6-hetaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds and the use thereof for controlling pathogenic fungi: e

20080227797 - Pyridopyrimidine derivatives as pde4 inhibitors for the treatment of inflammatory and immune diseases: The present invention provides a compound of a formula (I): [Chemical formula should be inserted here. Please see paper copy] wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease... Agent: Fish & Richardson P.C.

20080227798 - Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor: e

20080227799 - Cxcr4 antagonists including heteroatoms for the treatment of medical disorders: The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors. The compounds provided interfere with the binding of SDF1 to the receptor. These compounds are particularly useful for treating... Agent: King & Spalding LLP

20080227800 - Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome: The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of FIP1L1-PDGFRα-induced or TEL-PDGFRβ-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, and to a method of treating hypereosinophilic syndrome,... Agent: Novartis Corporate Intellectual Property

20080227801 - Pharmaceutical compositions containing erythrina mulungu derivatives, processes for their production and uses thereof: The present invention provides the use of molecules for cholinergic serotonergic and/or gabaergic system models, revealing pharmaceutical compositions comprising 11-OH-erythravine, erythravine, erythrartine, pharmaceutically acceptable isotherals, salts, byproducts and/or solvates thereof, optionally containing other Erythrine byproducts, for the treatment of anxiety disorders; processes for obtaining said pharmaceutical compositions are also revealed.... Agent: Smith, Gambrell & Russell

20080227802 - Agent for suppressing development of tolerance to narcotic analgesics: A medicament for suppressing development of tolerance to analgesic effect induced by administration of a narcotic analgesic such as morphine, which comprises an antagonist of the vasopressin receptor 1b as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20080227803 - Indolomorphinan derivative having carboxy in 6'-position: m

20080227804 - Polymorphic forms of naltrexone: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.... Agent: Elmore Patent Law Group, PC

20080227805 - Sustained release parenteral formulations of buprenorphine: An oil-in-water buprenorphine formulation including buprenorphine and a surfactant that emulsifies the buprenorphine in oil, wherein the drug release is controlled by varying the oil concentration and/or pH. A buprenorphine aqueous suspension formulation including a free base buprenorphine and a suspension stabilizer. A buprenorphine oil formulation including a buprenorphine salt... Agent: Paul D. Yasger Abbott Laboratories

20080227807 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20080227806 - Novel drugs for dementia: The invention is directed to compounds that are prodrugs containing a chemical delivery system (CDS) moiety and a cysteine protease inhibitor moiety. The CDS moiety targets the prodrug to the brain or central nervous system. The cysteine protease inhibitor inhibits cysteine proteases upon release from the prodrug. Cysteine protease inhibitors... Agent: Knoble, Yoshida & Dunleavy

20080227808 - Substituted phenylether-thienopyridone compounds with antibacterial activity: Novel bicyclic heteroaromatic compounds are provided that are inhibitors of bacterial methionyl tRNA synthetase (MetRS). Compounds of the invention generally have a left hand side phenylether constituent and a right hand side thienopyridone constituent. Also disclosed are methods for their preparation and their use in therapy as antibacterial agents, particularly... Agent: Swanson & Bratschun, L.L.C.

20080227809 - Arylalkylamine vanadium (v) salts for the treatment and/or prevention of diabetes mellitus: This invention provides compounds and pharmaceutical compositions thereof for treating human type 1 and type 2 diabetes, particularly insulin-resistant diabetes.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080227811 - Spiro substituted compounds as angiogenesis inhibitors: The present invention relates to spiro (tetracarbon) substituted compound of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the... Agent: G. Paul Chen / Advenchen Labs

20080227810 - 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR. Also provided are methods of making such compounds and pharmaceutical compositions.... Agent: Bell, Boyd & Lloyd LLP

20080227812 - Spiro substituted compounds as angiogenesis inhibitors: The present invention relates to spiro (tetracarbon) substituted compound of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the... Agent: G. Paul Chen / Advenchen Labs

20080227813 - Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration: The present invention relates to methods for treating diseases, conditions or disorders using hydroxyamine compounds, and in particular, N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride (Compound I) alone or in combination with one or more other therapeutic agents for the treatment of conditions, disorders or diseases associated with neurodegeneration in the central nervous system. Additional... Agent: Ropes & Gray LLP

20080227814 - Selective estrogen receptor modulators: The present invention relates to a selective estrogen receptor modulator selected from the group consisting of: (I) or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.... Agent: Eli Lilly & Company

20080227815 - Crystal of indole derivative having piperidine ring and process for production thereof: A crystal of 1-[1-[2-(7-methoxy-2,2-dimethyl-4-oxochroman-8-yl)-ethyl]piperidin-4-yl]-N-methyl-1H-indole-6-carboxamide fumarate which has peaks at chemical shifts of about 124.0 ppm and about 26.8 ppm in a 13C solid NMR spectrum.... Agent: Birch Stewart Kolasch & Birch

20080227816 - Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases: Methods of treating, preventing and/or managing central nervous system disorders, such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) and related syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone... Agent: Jones Day

20080227817 - New salt i: The invention provides N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methyl-propyl)oxy]-4-hydroxyphenyl}acetamide benzoate or a solvate thereof, pharmaceutical compositions containing the salt or solvate and use of the salt or solvate in therapy.... Agent: Fish & Richardson P.C.

20080227818 - Use of saredutant or its pharmaceutically acceptable salts in the treatment of mixed anxiety-depression disorders: The present invention relates to the use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of mixed anxiety-depression disorders.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080227819 - Method for identifying the agonistic activity of a target compound on a potassium channel: A method for identifying the agonistic activity of a target compound on a potassium channel by a) providing a population of cells expressing a potassium channel and, optionally providing, a protein-based fluorescent-optical voltage sensor, b) if necessary, incubating the cells with a voltage-sensitive fluorescent dye, c) adding the target compound... Agent: Crowell & Moring LLP Intellectual Property Group

20080227820 - Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents: m

20080227821 - N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors: 3-[3-(2-Chloro-pyridin-4-ylamino)-6-ethoxy-1-methyl-1,4-dihydro-indeno[1,2-c]pyrazol-7-yloxy]-propan-1-ol, and N-oxides, pharmaceutically acceptable salts, solvates, tautomers and stereochemical isomers thereof and the uses of such compounds as inhibitors of tubulin polymerization and for the treatment of solid tumors. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for... Agent: Philip S. Johnson Johnson & Johnson

20080227822 - Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i: [

20080227823 - Amide derivatives as calcium channel blockers: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing both a diamide and aromatic functionality are disclosed of the general formula (1) where X1 and X2 are linkers.... Agent: Morrison & Foerster LLP

20080227824 - 5-(phenylisoxazolylethoxy) - triazol- 3 -yl substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders: The present invention is directed to novel compounds of formula (I)/(II)/(III), their use in therapy and pharmaceutical compositions comprising said novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20080227825 - Formulation: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.... Agent: Novartis Corporate Intellectual Property

20080227826 - Inhibitors of histone deacetylase: i

20080227827 - Compounds that abrogate dna damage induced cell cycle g2 checkpoint and/or augment anti-cancer activity of dna-damaging treatments: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080227828 - Aryl ureas with angiogenisis inhibiting activity: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.... Agent: Millen, White, Zelano & Branigan, P.C.

20080227829 - Neurogenic compounds: The invention relates to method(s) of use of the compound(s) described herein, e.g. method for stimulating neurogenesis, including in vitro neurogenesis, by contacting neuronal progenitor cells with an effective amount of the compound(s) described herein; method for treatment of a subject in need of treatment with a neurogenic compound; and/or... Agent: Nada Jain, P.C.

20080227830 - Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension: The present invention is directed to methods of treating neurally mediated hypotension. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, that can be administered to a patient for the treatment of neurally mediated hypotension.... Agent: Alston & Bird LLP

20080227831 - Food extracts for treatment of lipoprotein abnormalities and skin diseases and skin disorders: The present invention is directed to N-methylnicotinamide containing food extracts, and their use in treating lipoprotein abnormalities and skin diseases and disorders.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080227832 - Modified coffee, method of roasting coffee bean, coffee-like supplement and auxiliary food: A modified coffee containing 3 mg or more of a nicotinic acid compound and 10 mg or more of a Maillard reaction product per 10 g of roasted coffee beans. A coffee-like supplement containing at least one nicotinic acid compound, at least one Maillard reaction product, and/or at least one... Agent: Birch Stewart Kolasch & Birch

20080227834 - Derivatives of 2-aminothiazoles and 2-amino-oxazoles, processes for their preparation and their use as pharmaceutical compositions: in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080227833 - Oxa- and thiadiazoles and their use as metalloproteinase inhibitors: Compounds formula (IA) or (IB), wherein W represents HO(C═O)—, HONH(C═O)— or H(C═O)N(OH)—; X represents —O— or —S—; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metal oproteinases, in particular MMP9 and/or MMP12.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080227835 - Heterocyclic amide derivatives useful as microbiocides: The invention relates to a fungicidally active compound of formula (I): where Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, the ring being substituted by the groups R6, R7 and R8; R1 is hydrogen, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080227836 - Stable solid oral dosage forms of valsartan: A stable solid oral dosage form comprising valsartan or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable additives such as sugar (derivatives) and cellulose (derivatives). The active agent is present in an amount less than 35% by weight based on the total weight of the solid oral dosage form. Disclosed... Agent: Merchant & Gould PC

20080227837 - Novel compounds: s

20080227838 - Method for neuroprotection with glycoluril derivatives: A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080227839 - Kinase inhibitors: The present invention provides kinase inhibitors of Formula I:... Agent: Eli Lilly & Company

20080227840 - Bicyclic 5-hydroxypyrazolines, method for producing the same and agents comprising the same: e

20080227841 - Intravesical apaziquone administration following transurethral resection: Bladder cancer treatments include the intravesical administration of apaziquone immediately (e.g. within about 6 hours) following transurethral resection.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080227842 - Non-fluorescent chlorophyll catabolites: The invention relates to a compound of formula (I), or a pharmacologically or cosmetically acceptable salt or derivative thereof, wherein R1 to R5 are selected from the groups R1 representing -alkyl, -vinyl, —CHOH—CH2OH, R2 representing H, —OH, —Oalkyl, —Oacyl, saccharide groups, modified saccharide groups (e.g. malonylated), R3 representing —H, —OH,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080227843 - Therapeutic use of n-(1h-indolyl)-1h-indole-2-carboxamide derivatives: e

20080227845 - Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination: The invention relates to a combination which comprises (a) a cyclooxygenase-2 inhibitor (“COX-2 inhibitor”) and (b) a histone deacetylase inhibitor (“HDAI”) for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of pre-malignant colon lesions or a colon cancer or other malignancies in a mammal, particularly a... Agent: Novartis Corporate Intellectual Property

20080227844 - Methods for treatment with bucindolol based on genetic targeting: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor... Agent: Fulbright & Jaworski L.L.P.

20080227846 - Methods of treating juvenile type 1 diabetes mellitus: The present disclosure describes methods for treating or preventing Type 1 diabetes mellitus in juveniles, particularly in juveniles newly diagnosed with Type 1 diabetes. This prevention or treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent... Agent: Fulbright & Jaworski L.L.P.

20080227847 - Novel salts of fumaric acid monoalkylesters and their pharmaceutical use: The present invention relates to novel amino acid salts of fumaric acid monoalkylesters. The salts are suitable for use as active substances in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders.... Agent: Darby & Darby P.C.

20080227848 - Assays: A method of identifying an agent which modulates 2-oxoglutarate dependent oxygenase activity, the method comprising contacting a 2-oxoglutarate dependent oxygenase and a test agent in the presence of a substrate comprising one or more ankyrin repeat, or fragment thereof, in conditions under which the substrate is hydroxylated in the absence... Agent: Clark & Elbing LLP

20080227849 - Orally disintegrable solid preparation comprising povidone-iodine: An orally disintegratable solid preparation comprising povidone-iodine as an active ingredient, which is obtained by direct powder compression of a mixture containing a granular sugar alcohol and povidone-iodine, wherein the mixture does not contain a basic ingredient and is not subjected to wet granulation. High quality solid preparation as an... Agent: Greenblum & Bernstein, P.L.C

20080227850 - Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms: The present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the prevention and treatment of vasomotor symptoms, such as hot flush, caused by, inter alia, thermoregulatory dysfunctions.... Agent: Wyeth Patent Law Group

20080227851 - Laulimalide and laulimalide analogs: Novel laulimalide analogs, methods for the treatment of proliferative disease and processes for the synthesis of laulimalide and novel laulimalide analogs are described.... Agent: King & Spalding LLP

20080227852 - Schweinfurthin analogues: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.... Agent: Viksnins Harris & Padys Pllp

20080227853 - Androgene membrane receptor agonist: Disclosed is a method of treating or preventing a disorder influenced by the action of a membrane androgen receptor, wherein a patient suffering or expected of suffering of such disorder is administered in pharmaceutically effective amounts an agonist of the membrane androgen receptor, said agonist being selected among the group... Agent: Sughrue Mion, PLLC

20080227854 - Compound 3-(1, 1-dimethyl-allyl)-6-hydroxy-chromen-2-one and its pharmaceutically acceptable salts thereof: Accordingly the present invention describes the anti-inflammatory compound 3-(1,1-dimethyl-allyl)-6-hydroxy-chromen-2-one isolated from the Ruta graveolens L. plant for the inhibition of inos gene thereby reducing nitric oxide level that increases significantly in inflammatory diseases. Thus the present invention relates to the discovery of lead compound for therapeutic intervention of the inflammatory... Agent: Dla Piper US LLP

20080227855 - Solid dispersion of hydrophobic bioactive: A stable composition of an amorphous component (such as a bioactive) and a carrier polymer is formed by mixing a bridging polymer with the bioactive and the carrier polymer, wherein the bridging polymer is a hydrogen bond donor to both the bioactive and the carrier polymer, thereby forming a composition... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080227856 - Materials and methods for creating customized compositions having a temporary visual indicator: The present invention relates to novel compositions, which provide an indicator for location and/or concentration of the composition during application. Following application, the indicator is no longer visible to the user. In one embodiment, the indicator is a compound that is visible at a first pH and not visible at... Agent: Margaret Efrom Saliwanchik, Lloyd & Saliwanchik

20080227857 - N-alkylcarbonyl-amino acid ester and n-alkylcarbonyl-amino lactone compounds and their use: The present invention generally relates to refreshing, soothing, and cooling compounds that affect sensory processes. More particularly, the present invention pertains to certain N-alkylcarbonyl-amino acid ester and N-alkylcarbonyl-amino lactone compounds as described herein; compositions and articles comprising such compounds; and methods of treatment, for example, methods of alleviating the discomforts... Agent: Michael Best & Friedrich LLP

20080227858 - Inhibitors of matrix metalloproteinase: e

20080227859 - Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same: The present invention relates to a tetrafluorobenzyl derivative and a pharmaceutical composition for prevention and treatment of acute and chronic neurodegenerative disease in central nervous system and ophthalmic diseases containing the same. The tetrafluorobenzyl derivative of the present invention can effectively be used to prevent and treat chronic neurodegenerative diseases... Agent: Seed Intellectual Property Law Group PLLC

20080227860 - Composition comprising oleic acid and the use thereof: The present invention relates to the pharmaceutical composition and health care food comprising oleic acid having neuroprotective activity. The oleic acid of the present invention has potent neuroprotective effect and recovery effect on neurological behavior. Therefore, it is useful as the therapeutics for the prevention or treatment of degenerative brain... Agent: Lucas & Mercanti, LLP

20080227861 - Inhibition of allergic contact dermatitis by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester: It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) and/or one of its lower alkyl derivatives can be used to treat allergic contact dermatitis associated with irritating oils such as catechol-containing plant-derived antigens such as poison ivy, poison oak, poison sumac and Asian lacquer tree and oils containing capsaicin.... Agent: Eugenia S. Hansen Hemingway & Hansen, LLP

20080227862 - Methods of treating cancer with hdac inhibitors: The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML) and Hairy Cell Leukemia, by administration of pharmaceutical... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080227863 - Organic compounds: e

20080227864 - Lhr1 activators as medicaments: Methods or prevention or treatment of diseases or conditions caused by low plasma apoA-1 levels, the use of LRH1 activators in such methods and methods for identification of compounds useful in such treatment.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080227865 - Colipse-lipase inhibitors in the preparation of a pharmaceutical composition in order to prevent obesity: The present invention relates to novel colipase-lipase inhibitors of the general formulae to be used in the treatment of prophylaxis of obesity, as well as pharmaceutical compositions containing the same, and method for treating obesity using said compounds.... Agent: Gauthier & Connors, LLP

20080227866 - Hydroxyphenylalkadiones and their use for masking bitter taste and/or for intensifying sweet taste: e

20080227867 - Use of 4-hydroxychalcone derivatives for masking an upleasant taste:

20080227868 - Composition comprising an hdac inhibitor in combination with a retinoid: The present invention is directed to compositions which contain a combination of at least one histone deacetylase inhibitor (HDAC inhibitor) and a retinoid. The composition is in particular a cosmetic preparation. It was found that the combination of an HDAC inhibitor and retinol or a derivative thereof is in particular... Agent: Nixon & Vanderhye, PC

20080227869 - Substituted nitrobenzene derivatives as pharmaceutical and other uses thereof: e

20080227870 - Carcinogen solvents in reducing the carcinogen concentration of cells: The present invention describes biologically compatible inert perfluorocarbon liquids capable of removing carcinogens from cells and thereby reducing the risk of cancerous cell transformation. This invention can be used to reduce the build-up of carcinogens, and thus be used as prophylactic medicaments in reducing the risk of chemically induced cancerous... Agent: Greenberg Traurig, LLP

20080227871 - Ampholytic copolymer, production thereof, and use of the same: The following invention relates to copolymers containing silicone groups which comprise, in copolymerized form, at least one monomer with an ionogenic and/or ionic group and at least one crosslinking monomer, to a process for the preparation of such copolymers containing silicone groups by precipitation polymerization, and to the use of... Agent: Connolly Bove Lodge & Hutz, LLP

20080227872 - Method for the preparation of 1-benzotriazolyl carbonate esters of poly (ethylene glycol): The invention provides a method for preparing a 1-benzotriazolylcarbonate ester of a water-soluble and non-peptidic polymer by reacting a terminal hydroxyl group of a water-soluble and non-peptidic polymer with di(1-benzotriazolyl)carbonate in the presence of an amine base and an organic solvent. The polymer backbone can be poly(ethylene glycol). The 1-benzotriazolylcarbonate... Agent: Nektar Therapeutics

20080221012 - Activatable clostridial toxins: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.... Agent: Dean G. Stathakis Allergan, Inc. -t2-7h

20080221016 - Cd25+ differential markers and uses thereof: The present invention is directed to methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of autoimmune disorders, transplant rejection and cancer. In particular, the present invention is directed to the identification of novel targets which are CD25+ differential markers. The present invention... Agent: Fitzpatrick Cella Harper & Scinto

20080221015 - Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof: The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080221014 - Method of diagnosing and treating glioma: The present invention is directed to methods and compositions for the diagnosis, prognosis and treatment of glioma in mammals.... Agent: Genentech, Inc.

20080221013 - Neurobiological compositions: Disclosed herein are compositions and methods for the treatment or prevention of neurological disorders using lynx compounds. The invention further discloses compositions and methods for the modulation of acetylcholine receptor activity.... Agent: Julie Michiko Miwa

20080221017 - Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans cell migration: The invention concerns a pharmaceutical or cosmetic composition, characterized in that it comprises at least a compound for inhibiting Langerhans' cell migration, said active compound being selected in the group consisting of protein kinase C (PKC) inhibiting compounds, matrix metalloprotease (MMP) inhibiting compounds, and combinations thereof, and at least a... Agent: Foley And Lardner LLP Suite 500

20080221011 - Targeting complement factor h for treatment of diseases: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which... Agent: Morrison & Foerster LLP

20080221018 - Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto: The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and... Agent: Townsend And Townsend And Crew, LLP

20080221019 - Treatment of inclusion body myositis: The present invention relates to the field of myopathy and particularly to the treatment and/or prevention of inclusion body myositis (IBM). A composition is provided, which comprises as an active ingredient either growth hormone, a secretagogue thereof or a mixture thereof, to cure IBM or suppress the symptoms associated therewith.... Agent: Oppedahl Patent Law Firm Llc - Wslg

20080221024 - Analogs of shk toxin and their uses in selective inhibittion of kv1. 3 potassium channels: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments the chemical entity attached to the ShK toxin may comprise... Agent: Stout, Uxa, Buyan & Mullins LLP

20080221034 - Canine specific growth hormone releasing hormone: A composition and a method of increasing growth hormone (“GH”) values in a canine or dog, and more specifically, a canine- or dog-specific growth hormone releasing hormone (“dGHRH”), or functional biological equivalent thereof. The dGHRH is an isolated composition or a nucleic acid molecule that encodes the dGHRH or functional... Agent: Pepper Hamilton LLP

20080221027 - Composition and methods for the treatment of duchene muscular dystrophy: Patients are treated for muscular dystrophy by artificially increasing effective sarcospan activity in the patient's muscle tissue. Sarcospan (or fragments thereof) can be administered directly to the tissue, or their production can be induced by gene therapy. Modifications are also contemplated to be effective, including for example, a lipid, TAT... Agent: Fish & Associates, Pc Robert D. Fish

20080221028 - Compositions and methods for treating atherosclerosis: Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis... Agent: Licata & Tyrrell P.c.

20080221020 - Dendrimers as molecular translocators: Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine... Agent: Foley & Lardner LLP

20080221032 - Factor viia-polysialic acid conjugate having prolonged in vivo half-life: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal,... Agent: Attn: Patent Administration Department Baxter Aktiengesellschaft

20080221030 - Inhibition of wet type age related macular degeneration (amd) by adiponectin or acrp 30: The present invention provides new methods of treating wet type of age related macular degeneration by administering adiponectin (APN) or a functional fragment derived therefrom. One of the pathological complications of age related macular degeneration (AMD) is choroidal angiogenesis or choroidal neovascularization (CNV). The inventors discovered that the level of... Agent: Greenlee Winner And Sullivan P C

20080221031 - Kallikrein inhibitors and anti-thrombolytic agents and uses thereof: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion... Agent: Lowrie, Lando & Anastasi, LLP

20080221037 - Methods and compositions for treating disorders involving excitotoxicity: It is shown here that hedgehog polypeptides possess novel activities beyond phenotype specification. Using cultures derived from the embryonic day 14.5 (E14.5) rat ventral mesencephalon, we show that hedgehog is also trophic for dopaminergic neurons and other neurons which are sensitive to exotoxicity.... Agent: Ropes & Gray LLP

20080221029 - Methods for treatment of thiol-containing compound deficient conditions: Certain embodiments in the present invention provide for methods for therapy of lung diseases and other conditions such as infection are provided. In certain embodiments, the methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e., ABC transporters such as MDR-1 or MRP-2)... Agent: Faegre & Benson LLP Patent Docketing

20080221033 - Monitoring of cardiac natriuretic peptides during diagnosis, management, and treatment of cardiac diseases: In a cardiac monitoring method, at east an inactive natriuretic peptide (22) and an active natriuretic peptide (20) are assayed in a biological sample taken from a patient. Both the inactive and active natriuretic peptides are produced in the patient responsive to cardiac stress. A therapeutic agent (26), such as... Agent: Philips Intellectual Property & Standards

20080221021 - Novel corticotropin-releasing factor receptor 1 (crfr1) agonist: The present invention relates to a compound which is highly selective for CRFR1 without having any significant cross-reactivity for corticotropin-releasing-factor-receptor-2 (CRFR2) and/or corticotropin-releasing-factor-binding protein (CRFBP), said compound comprising or alternatively consisting of the amino acid sequence as depicted in SEQ ID No: 1. In another aspect, the present invention relates... Agent: Birch Stewart Kolasch & Birch

20080221035 - Ply-gbs mutant lysins: Methods, compositions and articles of manufacture useful for the treatment of various Group B streptococci (GBS) bacteria using various lysins, including certain PlyGBS mutant lysins, are provided.... Agent: Indianapolis Office 27879 Brinks Hofer Gilson & Lione

20080221026 - Process for manufacture of nematode-extracted anticoagulant protein (nap): The present invention provides a process for manufacture of purified Nematode-extracted Anticoagulant Proteins (NAPs), wherein the NAP manufactured by the claimed process method is a NAP drug substance that can be formulated as a NAP drug product. The present invention provides NAP drug substances and NAP drug products manufactured by... Agent: Robins & Pasternak

20080221022 - Prouroguanylin, and synthetic analogs or proteolytic cleavage products derived from it, as therepeutic and diagnostic agents for diseases involving salt and/or fluid homeostasis: A method for treating a disorder characterized by salt retention, fluid retention, and combinations thereof. A method for determining the presence of or the progression of a disorder characterized by salt retention, fluid retention, salt loss, fluid loss, and combinations thereof. An immunoassay kit for detecting a level of prouroguanylin... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080221036 - Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions: m

20080221023 - Use of protein hydrolysates for the manufacture of a medicament for prophylaxis and/or treatment of a dpp-iv mediated condition: Disclosed is the use of one or more protein hydrolysates for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, like, for example, obesity, type II diabetes mellitus, autoimmune diseases.... Agent: The Webb Law Firm, P.c.

20080221025 - Use of trpc channel for the treatment of a cardiovascular disease: The invention refers to the use of a TRPC channel, an inactivating mutant thereof, or a nucleotide sequence coding for the TRPC channel or for the inactivating mutant for the production of a medicament for the treatment of a cardiovascular disease and a method of screening a modulator of the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080221038 - Compounds for control of appetite: This invention relates generally to peptides including tripeptides and to methods for pharmaceutical treatment of mammals using such tripeptides and analogs thereof. More specifically, the invention is directed to neuropeptide Y (“NPY”) receptor antagonists and agonists including O-glycosylated tripeptides, i.e. O-glycopeptides, and extended tripeptides, and their analogs, as well as... Agent: Wood, Herron & Evans, LLP

20080221039 - Kinin antagonists for treating bladder dysfunction: The present invention is related to the use of a kinin receptor antagonist for the manufacture of a medicament for the treatment and/or prevention of bladder dysfunction, whereby the kinin receptor is selected from the group comprising B1 and B2 receptors.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080221042 - Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb): The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080221040 - Compositions and methods for the control of mammary cell number: The present invention provides new methods and uses of peptides in effecting a reduction in mammary cell number. The discovery that these peptides reduce mammary cell number further enables the use of these peptides in the treatment of cancer where the peptides can be used to reduce cell number and... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080221041 - Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension: The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to hypertension, especially in medical interventions involving dilatation and remodeling of arterial blood vessels, either in the pulmonary or in the systemic circulation. The peptides which can be... Agent: Winstead Pc

20080221043 - Dendritic molecular intracellular transporters and methods of making and using same: and at least one guanidinium residue, wherein m is zero or a positive integer. Also disclosed are methods of preparing the disclosed compounds. Also disclosed are methods of intracellular delivery comprising administering the disclosed compounds and compositions to a subject. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount... Agent: Needle & Rosenberg, P.c.

20080221044 - Composition for inhibiting the onset of arteriosclerosis and inhibition method: [Means for Resolution] The composition for inhibiting the onset of arteriosclerosis is characterized by comprising D-psicose as an active ingredient for an antiatherogenic action. The antiatherogenic action as described above includes an action of inhibiting or reducing the expression of a chemokine or a cytokine related to arteriosclerosis in vivo... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080221045 - Hepatic function-improving agent: An object of the present invention is to provide a means for improving hepatic function of mammals including humans to normal condition. The present invention achieves the above object by providing a hepatic function-improving agent comprising α-glucosyl-hesperidin as an effective ingredient.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080221047 - Aminoakyl methacrylate copolymer e for maintaining solubility of poorly-soluble drug: A pharmaceutical composition comprising aminoalkyl methacrylate copolymer E, an acidic substance, and a poorly-soluble drug, wherein the aminoalkyl methacrylate copolymer E and the acidic substance are uniformly mixed, and solubility of the poorly-soluble drug is maintained for at least 30 minutes is disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080221048 - Lyophilized azithromycin formulation: The invention provides among other things a stable, sterile pharmaceutical formulation comprising lyophilized azithromycin and ethanol. The invention also provides a method of producing a stable, sterile pharmaceutical product comprising lyophilized azithromycin. The invention also provides a pharmaceutical dosage form comprising the pharmaceutical formulation, as well as a method of... Agent: Leydig Voit & Mayer, Ltd

20080221046 - Macrolides with anti-inflammatory activity: The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides substituted at the 4″ position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080221049 - Free-flowing lyophilized tobramycin formulation: The invention provides among other things a stable, sterile pharmaceutical formulation comprising lyophilized tobramycin, wherein the lyophilized tobramycin is in the form of a free-flowing powder. The invention also provides a method of producing a stable, sterile pharmaceutical product comprising lyophilized tobramycin. The invention also provides a pharmaceutical dosage form... Agent: Leydig Voit & Mayer, Ltd

20080221055 - Compositions and methods for inhibiting expression of huntingtin gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The... Agent: Lowrie, Lando & Anastasi, LLP A2038

20080221056 - Early detection and prognosis of colon cancers: We have developed a transcriptome-wide approach to identify genes affected by promoter CpG island hypermethylation and transcriptional silencing in colorectal cancer (CRC). By screening cell lines and validating tumor specific hypermethylation in a panel of primary human CRC samples, we estimate that nearly 5% of all known genes may be... Agent: Banner & Witcoff, Ltd.

20080221051 - Formulations comprising antisense nucleotides to connexins: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation... Agent: Duane Morris LLP

20080221054 - Inhibiting gene expression with dsrna: The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded RNA (dsRNA).... Agent: Lisa A. Haile, J.d., Ph. D. Dla Piper Us LLP

20080221050 - Method for diagnosing or predicting susceptibility to optic neuropathy: Disclosed is a set of genetic polymorphisms linked to optic neuropathy including glaucoma and Leber's disease. Those polymorphisms are useful for diagnosing and predicting susceptibility to optic neuropathy.... Agent: Sughrue Mion, Pllc

20080221052 - Modulation of wrn-mediated telomere-initiated cell signaling: The use of modulators of WRN is described. Activators of WRN may be used to induce growth arrest, apoptosis or proliferative senescence, whereas inhibitors of WRN may be used to reduce growth arrest, apoptosis or proliferative senescence. Methods of identifying modulators of WRN are also described.... Agent: Howrey LLP - Dc

20080221059 - Novel treatment tool for cancer: rna interference of bcas2: The present invention provides three BCAS2 related nucleotide sequences. The present invention also provides a composition comprising a nucleotide sequence of small interfering RNA of BCAS2 gene. The present invention further provides a method for treating p53 containing cancer comprising administrating a subject with an effective amount of the said... Agent: Wpat, Pc Intellectual Property Attorneys

20080221053 - Rna aptamers and methods for identifying the same: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.... Agent: King & Spalding LLP

20080221057 - Secreted protein ccdc80 regulates adipocyte differentiation: Disclosed herein are methods of modulating adipogenesis. The methods include contacting a cell expressing the Ccdc80 gene with an agent that modulates the expression or activity of the Ccdc80 gene or Ccdc80 protein. Further disclosed herein are methods of treating conditions such as obesity, insulin resistance, and/or type 2 diabetes... Agent: Wyeth Patent Law Group

20080221058 - Tumor-specific vector for gene therapy: The invention relates to a vector for the gene therapeutic treatment of tumors, especially in connection with radiotherapy. Said vector is provided with a therapeutic gene in the DNA sequence thereof. The gene is controlled by the promoter for the catalytic subunit of the telomerase or by the promoter for... Agent: Knobbe Martens Olson & Bear LLP

20080221060 - Therapeutic compounds: Use of compounds of general formula (A) as medicaments is described, in particular for the treatment of pain or inflammation; wherein: (I) when X=OH, R2=NH2, R5=CH2OH, R6=H, R1 is C5-C6 alkoxy, OCH2Cyclopropyl, O-(2,2,3,3-tetrafluoro-cycloButyl), phenoxy, substituted phenoxy, OCH2CH2OH, or OCH2CHF2, (5-indanyl)oxy, C1, C2, C5, or C6 alkylamino, (R) or (S)-sec-Butylamino, C5... Agent: Fish & Richardson Pc

20080221061 - Lung-targeted drugs: Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or glycerol phosphate ethers.... Agent: Jones Day

20080221063 - Heterocyclic sulfonamide derivatives as inhibitors of factor xa: The invention relates to heterocyclic derivatives of formula (I), Chemical formula should be inserted here. Please see paper copy wherein R1 is hydrogen or C1-3alkyl; R2 is selected from hydroxy, C1-5alkyl, carboxy, cyano, tetrazolyl, N—C1-5alkyltetrazolyl, oxazolyl, C1-5oxazolyl, isoxazolyl, C1-5 isoxazolyl, hydroxyC1-5alkyl, carboxy C1-5alkyl, C1-5alkoxyoxo C1-5alkyl, carbamoyl, C1-5alkylcarbamoyl, di(C1-5alkyl)carbamoyl, C1-5alkylcarbamoyl C1-4alkyl,... Agent: Pepper Hamilton LLP

20080221062 - Hyaluronic acid derivative and drug containing the same: A hyaluronic acid derivative in which an anti-inflammatory drug is bound to hyaluronic acid through a covalent bond via a spacer having a biodegradable region, and a production process thereof.... Agent: Sughrue-265550

20080221064 - Medicinal composition for ophthal use containing acetylated hyaluronic acid: The present invention provides an ophthalmic pharmaceutical composition containing acetylated hyaluronic acid and a pharmacologically acceptable carrier. Preferably, the average molecular weight of the acetylated hyaluronic acid is 10,000 to 1,000,000, and the acetyl group substitution number is from 2.0 to 4.0. In a preferred embodiment, this ophthalmic pharmaceutical composition... Agent: Hamre, Schumann, Mueller & Larson, P.c.

20080221065 - Organic compounds: Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration.... Agent: Novartis Corporate Intellectual Property

20080221066 - Modified hydroxypolymer conjugates with killing effect on tumor cells: The present invention is related to a modified hydroxypolymer conjugates preferably a guanidine-dextran conjugate having a tumor cell killing activity. The modified hydroxypolymer conjugate is used as medicine, particularly for manufacturing a medicine or tumor killing composition for treating tumors. A method for producing said hydroxypolymer conjugate and a method... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080221068 - Anti-tumor agents: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in... Agent: Wolf Greenfield & Sacks, P.c.

20080221069 - Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders: The present invention is directed to novel compounds according to formula (I) wherein R1, R2, and X are as defined herein. The invention also discloses methods of preparation, pharmaceutical compositions, and methods of disease treatment utilizing pharmaceutical compositions comprising these compounds. The compounds of this invention are novel therapeutic agents... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080221067 - Wood preservative composition: A wood preservative composition comprising a mixture of a fungicide which is a combination of a boric acid ester, which is soluble in an organic solvent and has a sterically hindered di-alcohol or tri-alcohol group, such as trihexylene glycol biborate, an organo-iodine compound, a triazole, and a synthetic pyrethroid insecticide,... Agent: Roetzel And Andress

20080221070 - Methods and compounds for the targeted delivery of agents to bone for interaction therewith: Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; a Linking Portion (RL) connecting the Bone Targeting Portion and the Bone Active Portion. The Bone Active Portion is... Agent: Stites & Harbison Pllc

20080221071 - Compositions for providing vitamin d year round and uses thereof: Methods for enhancing the ability of an individual, exposed to sunlight, to produce vitamin D via the skin. Pharmaceutical compositions comprising provitamin D and at least one of lumisterol and tachysterol and analogs and derivatives thereof are also disclosed.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080221072 - Fatty acid modified forms of glucocorticoids: t

20080221073 - Nitrooxy derivatives of glucocorticoids: The invention relates to new steroids nitrooxyderivatives, to topical pharmaceutical formulations thereof, and their use for treating skin or mucosal membrane diseases or disorders. These new steroids nitrooxyderivatives have an improved pharmacological activity and enhanced local tolerability.... Agent: Arent Fox LLP

20080221074 - Drug screen and treatment method: The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4α-fluoro-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3β,7α,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3α,7β,17β-triol and 4α-fluoro-17α-ethynylandrost-5-ene-3β,17β-triol-7-one.... Agent: Hollis-eden Pharmaceuticals, Inc.

20080221075 - Therapeutic uses for aminosterol compounds: A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may be produced including this pharmaceutical composition. Such pharmaceutical products may be used for the... Agent: Morgan Lewis & Bockius LLP

20080221076 - Crystalline sodium salt of cephalosporin antibiotic: The present invention relates to novel polymorph of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of crystalline Ceftiofur sodium of formula (I).... Agent: Clark & Elbing LLP

20080221077 - Ansamycin formulations and methods of use thereof: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock... Agent: Choate, Hall & Stewart LLP

20080221078 - Use of a cb1 antagonist for treating side effects and negative symptoms of schizophrenia: The present invention discloses and claims a method of treating cognition deficits in a patient suffering from schizophrenia by administering to said patient a therapeutically effective amount of a CB1 receptor antagonist as described herein. In another aspect, this invention also discloses and claims a combination of one or more... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080221079 - Pharmaceutical composition of quetiapine fumarate: A pharmaceutical composition comprising (i) quetiapine or a pharmaceutically acceptable salt thereof, especially quetiapine fumarate; (ii) a mixed excipient comprising an intimate admixture of polyvinylacetate and polyvinylpyrrolidone in a weight ratio from 5:2 to 10:2; and, optionally (iii) an acid especially fumaric acid.... Agent: Synthon Ip Inc

20080221080 - Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias: The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic... Agent: Novartis Corporate Intellectual Property

20080221081 - Polymorphs of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid s,s dioxide and methods of making and using the same: Disclosed herein are novel polymorphs of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide. Also described herein are novel pharmaceutical compositions comprising one or more 7-[(3 chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide polymorphs, methods of making, and related methods of treatment.... Agent: Philip S. Johnson Johnson & Johnson

20080221082 - Ligands of integrin receptors: The invention relates to the use of cyclic compounds as ligands of integrin receptors, in particular as ligands of the αVβ3 integrin receptor, the novel compounds themselves, their use, and pharmaceutical preparations comprising these compounds.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20080221083 - Heterobicyclic metalloprotease inhibitors: The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known... Agent: Amgen Inc.

20080221084 - Method for reducing infarction using vasopressin antagonist compounds, and compositions and combinations therefor: The present invention relates to a method for reducing infarction comprising administering to a patient ion need thereof a therapeutically effective amount of a composition comprising as an active ingredient a vasopressin antagonist compound and to a composition useful therefor. The present invention also relates to a method for reducing... Agent: Sughrue Mion, Pllc

20080221085 - Nicotinic receptor agonists for the treatment of inflammatory diseases: Nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases, and pharmaceutical compositions including nicotine receptor agonists or analogs or derivatives thereof. Compounds of formula wherein R1, R2, Xa and Ya are as defined herein are also provided.... Agent: Buchanan, Ingersoll & Rooney Pc

20080221086 - Novel inhibitors of glutaminyl cyclase: c

20080221087 - Substituted lactams as inhibitors of abeta protein production: having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the... Agent: Kelley Drye & Warren LLP

20080221088 - 3,4-substituted thiazoles as ampk activators: The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5′-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds.... Agent: Reddy Us Therapeutics, Inc

20080221089 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.... Agent: Rigel Pharmaceuticals Inc.

20080221090 - Hcv ns5b inhibitors: The invention encompasses compounds of Formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080221091 - Metalloprotease inhibitors containing a heterocyclic moiety: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a modified benzoxazine moiety, that exhibit an increased potency and selectivity in relation to currently... Agent: Amgen Inc.

20080221092 - Heterobicyclic metalloprotease inhibitors: The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds that exhibit an increased potency and selectivity in relation to currently known... Agent: Amgen Inc.

20080221093 - Metalloprotease inhibitors containing a heterocyclic moiety: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known... Agent: Amgen Inc.

20080221095 - Metalloprotease inhibitors containing a heterocyclic moiety: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity... Agent: Amgen Inc.

20080221094 - Metalloprotease inhibitors containing a squaramide moiety: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a squaramide moiety, that exhibit an increased potency and selectivity in relation to currently known... Agent: Amgen Inc.

20080221096 - Pyrido[3' ,2':4,5]furo[3,2-d]pyrimidine derivatives: wherein p and q are integers chosen from 0, 1, 2 and 3; A is either a direct bond or a group chosen from —CONR14—, —NR14CO—, —O—, —COO—, —OCO—, —S—, —SO— and —SO2—, wherein each R10, R11, R12, R13 and R14 are independently chosen from a hydrogen atom and a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080221098 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR,... Agent: Genomics Institute Of The Novartis Research Foundation

20080221099 - Dihydropteridinones for the treatment of cancer diseases: optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080221097 - Imidazopyridine derivatives as cannabinoid receptor ligands: The present invention relates to novel imidazopyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080221101 - Calcium receptor modulating agents: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.... Agent: Amgen Inc.

20080221102 - Composition and methods for modulating a kinase cascade: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080221100 - Soluble epoxide hydrolase inhibitors: Disclosed are urea compounds, stereoisomer, or pharmaceutical acceptable salt thereof, and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases,... Agent: Foley & Lardner LLP

20080221103 - New heterocyclic compounds: Provided herein are heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, wherein R1, R2, R3, R4 and R5 are as described herein. Further described herein in particular are heterocyclic compounds of the formula... Agent: Oliff & Berridge, Plc

20080221104 - Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis: Methods for reducing autoimmune induced inflammation, including rheumatoid arthritis in a subject in need of such therapy are disclosed.... Agent: Foley & Lardner LLP

20080221105 - Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders: Compounds, compositions, and methods for inhibiting the onset of metabolic syndrome and treating related disorders in a subject in need of such therapy are disclosed.... Agent: Foley & Lardner LLP

20080221106 - Arylamine ketones, their preparation methods, the pharmaceutical composition containing them and their use: Disclosed Arylamine ketones of formula (I), their preparation methods, the pharmaceutical compositions containing them and their use in preventing and/or treating the diseases related to the plaque-activating factors, especially in anti-inflammation and immunization, more especially in the treatment of the acute or chronic inflammation, such as, osteoarthritis, oarthritis deformans, etc.... Agent: Fay Sharpe LLP

20080221107 - Therapeutic agents: Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions... Agent: Pepper Hamilton LLP

20080221108 - Anthranilic acid derivatives as hm74a receptor agonists: Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2 and W, are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080221109 - Pesticidal substituted thioethers: The invention relates to the use of thioether derivatives of formula (I) wherein: R1 is an unsubstituted or substituted (C1-C6) alkyl, A is a divalent unit taken from the group CO, CR3(OR4), CR3(O—CO—R4), CR3(COOR4), C(═CR3R4), C(═CR3R4), C(═CR3—COOR4), C(═CR3—CN); X is an unsubstituted or substituted (C1-C3) alkylen, R2 is an unsubstituted... Agent: Frommer Lawrence & Haug

20080221110 - Compounds: Tricyclic nitrogen containing compounds and their use as antibacterials... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080221111 - Combination of a pd4 inhibitor and a tetrahydrobiopterin derivative: The invention describes the use of a PDE4 inhibitor in combination with BH4 or a BH4 derivative for the prevention and/or treatment of respiratory diseases.... Agent: Nath & Associates Pllc

20080221112 - New utilities of amide compounds: in which ring A and Ar1 are independently a monocyclic or bicyclic aromatic carbocyclic group or aromatic heterocyclic group, each of which may be optionally substituted, or the like; R is a hydrogen or the like; Z is oxygen or the like; Y1 and Y2 are a hydrogen, a lower... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080221113 - Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments:

20080221114 - 2-(cyclic aminocarbonyl) indoline derivative and medicinal composition containing the same: wherein X is an oxygen atom or a sulfur atom, R4 is a hydrogen atom, a C1-6 alkyl group, or other, R5 is a hydrogen atom or other; or a heteroaryl group or other optionally substituted with a halogen, a C1-6 alkyl, a C1-6 alkoxy, or other; R1 and R2... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080221115 - Use of long-chain alcohol derivatives for the treatment of alopecia areata: wherein R1 is C10-C24 alkenyl; R2 is H, C1-C6 alkyl, aryl, or aralkyl, where any aryl moiety may be unsubstituted or substituted by nitro, cyano, halo, hydroxyl, NR6R7, or CR8R8NR6R7, where R6, R7, and R8 each independently is H or C1-C6 alkyl; and R3 and R4 each independently is H... Agent: Cooper & Dunham, LLP

20080221117 - Urea derivatives as calcium channel blockers: Urea derivatives which comprise piperidine or piperazine rings and further substitution are effective in ameliorating conditions characterized by unwanted calcium ion channel activity.... Agent: Morrison & Foerster LLP

20080221118 - Tetrahydroquinoline derivatives: Compounds of the formula I, in which s, k, I, W, R1, R2, R3, and U have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.c.

20080221119 - Pyrrolo-pyridine kinase modulators: The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.... Agent: Wilson Sonsini Goodrich & Rosati

20080221120 - Modulation of aquaporin in modulation of angiogenesis and cell migration: The invention provides compositions, pharmaceutical preparations, and methods for modulating angiogenesis and/or cell migration in a subject having a cellular proliferative disease (e.g., cancer), or a disease or condition amenable to treatment by enhancing cellular proliferation and cell migration (e.g., angiogenesis), by modulating the activity of an aquaporin, such as... Agent: Bozicevic, Field & Francis LLP

20080221121 - Controlled release sterile injectable aripiprazole formulation and method: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A... Agent: Sughrue Mion, Pllc

20080221116 - Isoxazoline alpha 1a/1d adrenoreceptor antagonists: The present invention relates to isoxazolines useful as selective α1a/α1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and/or lower urinary tract symptoms as well as to pharmaceutical compositions comprising said compounds, processes to prepare these compounds, and the use of these compounds as α1a/α1d adrenoreceptor modulators in a... Agent: Philip S. Johnson Johnson & Johnson

20080221122 - Analogs of dehydrophenylahistins and their theapeutic use: e

20080221123 - Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment: The present invention relates to piperazinone compounds, pharmaceutical compositions containing those compounds and methods of treating tumors and cancer, among other disease states and conditions in mammalian patients, especially including humans.... Agent: Jeremy A. Cubert, Esq. Dickstein Shapiro LLP

20080221124 - Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4-[1, 3, 4-oxadiazole-2-yl] phenyl) pyridine-3-sulphonamide: N-(Methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-yl]phenyl)pyridine-3-sulphonamide ethanolamine salt its synthesis and its uses are described.... Agent: Astrazeneca R&d Boston

20080221125 - Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors: The present invention is directed to novel heterocyclic benzo[c]chromene derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot... Agent: Philip S. Johnson Johnson & Johnson

20080221126 - Use of hdac inhibitors for the treatment of myeloma: wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of myeloma, in particular multiple myeloma, especially myeloma which is resistant to conventional chemotherapy; to a combination comprising an HDAC inhibitor and a compound effecting apoptosis of myeloma... Agent: Novartis Corporate Intellectual Property

20080221127 - Ppar active compounds: Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ.... Agent: Foley & Lardner LLP

20080221128 - Metalloprotease inhibitors containing a squaramide moiety: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity... Agent: Amgen Inc.

20080221130 - Fungicidal 5-methyl-6-phenylpyrazolopyrimidin-7-ylamines: e

20080221129 - New compounds: including pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, and N-oxides thereof, said compounds being useful as inhibitors of stearoyl-CoA desaturase (SCD). The invention further relates to the use of compounds of the formula (I) for treatment of medical conditions in which the modulation of SCD activity is... Agent: Edwards Angell Palmer & Dodge LLP

20080221131 - Thienopyrimidinediones and their use in modulation of autoimmune disease: c

20080221132 - Multi-functional small molecules as anti-proliferative agents: The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the... Agent: Elmore Patent Law Group, Pc

20080221134 - 8-alkynylxanthines and derivatives: e

20080221133 - Compounds: R1 is selected from C1-C6 alkyl, and said C1-C6 alkyl is substituted with C1-C6 alkoxy; and at least one of said C1-C6 alkyl or said C1-C6 alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, as well as, to compositions containing at least... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080221135 - Combination therapy: This invention relates to a combination of anti-cancer compounds which comprises a) an orally effective taxane, and b) a thymidylate synthase inhibitor, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080221136 - Novel pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080221137 - Quinazolines useful as modulators of voltage gated ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20080221138 - Method of using saha and erlotinib for treating cancer: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo Attn: Patent Intake Customer No. 35437

20080221139 - Novel compounds: e

20080221140 - 1-[2',3' -dideoxy-3' c-(hydroxymethyl) - beta-d-erythro-pentofuranosyl] cytosine derivatives as hiv: Compounds of the formula (I) wherein: R1 is independently H1—OR3, —NHR4; C1-C4 alkyl; or, when n is 2, adjacent R1 together define an olefinic bond; R2 is H; or when the gem R1 is C1-C4 alkyl, that R2 may also be C1-C4 alkyl; or when the gem R1 is —OR3,... Agent: Birch Stewart Kolasch & Birch

20080221141 - Spirocyclic cyclohexane compounds useful to treat substance dependency: Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency.... Agent: Crowell & Moring LLP Intellectual Property Group

20080221142 - Eftu inhibitors or aminothiazoles and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080221144 - Controlled release formulations: The present invention relates to controlled release transmucosal formulations which mediate absorption and methods of use comprising a pharmaceutically active agent, preferably morphine, and a water soluble polymer, chitosan, and preferably one more antioxidants, one or more antimicrobial agents, and water.... Agent: Baker Botts L.l.p.

20080221143 - Morphine and morphine precursors: Methods and materials related to the use of morphine, morphine precursors (e.g., reticuline), and inhibitors of morphine synthesis or activity to treat diseases, to reduce inflammation, or to restore normal function are provided.... Agent: Fish & Richardson P.c.

20080221146 - Inhibitors of nucleophosmin (npm) and methods for inducing apoptosis: Nucleophosmin inhibitors are disclosed which inhibit the multimerization of nucleophosmin and the biological activity of nucleophosmin, such as the ability of nucleophosmin to inhibit apoptosis and inhibit cellular differentiation. These small molecule inhibitors are useful for treating diseases and disorders, such as cancer associated with dysregulated nucleophosmin expression. Methods for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080221145 - Pyrroloquinoline quinone drugs for treatement of cardiac injury and methods of use thereof: The invention includes compositions comprising substantially purified pyrroloquinoline quinone, that are useful in methods for the treatment and prevention of cardiac injury caused by hypoxia or ischemia. The invention also includes methods for the treatment and prevention of cardiac injury comprising contacting a composition of the invention with a human... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.c.

20080221147 - Method of inhibiting neurotrophin-receptor binding: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two... Agent: Gowling Lafleur Henderson LLP

20080221151 - 3-amino-2-phenylpyrrolidine derivatives: 3-amino-2-phenylpyrrolidine compounds useful as NK-1 antagonists, with pharmaceutical compositions and methods of treatment comprising same, are disclosed.... Agent: Pfizer Inc Steve T. Zelson

20080221152 - 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists: where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardiovascular and/or... Agent: Allergan, Inc.

20080221148 - Compounds and methods for kinase modulation, and indications therefor: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.... Agent: Foley & Lardner LLP

20080221149 - Novel 2-heteroaryl substituted benzothiophenes and benzofuranes 709: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080221150 - Prevention of neurodegeneration by macrolide antibiotics: The present disclosure describes the use of macrolide antibiotics to prevent neurodegeneration and to treat or prevent disease and conditions which involve neurodegeneration. While not being limited to a specific mechanism of action, in one embodiment, the macrolide antibiotics inhibit neurodegeneration caused by lysosomal and/or mitochondrial dysfunction. The present disclosure... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20080221154 - Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use: e

20080221153 - N3-substituted imidazopyridine c-kit inhibitors:

20080221155 - Novel quinuclidine derivatives and medicinal compositions containing the same:

20080221156 - Stable formulations of ace inhibitors, and methods for preparation thereof: The present invention provides stable formulations of ACE inhibitors, especially enalapril maleate, that can be manufactured in a time efficient, cost effective manner. Such formulations can be prepared simply and on a large industrial scale. The present invention also provides methods for the preparation of stable formulations of ACE inhibitors,... Agent: Cantor Colburn, LLP

20080221157 - Amide derivatives as inhibitors of histone deacetylase: The present invention relates to ketone derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.... Agent: Merck And Co., Inc

20080221159 - Inhibitors of human immunodeficiency virus replication: e

20080221158 - Novel 14 and 15 membered ring compounds:

20080221160 - Sulfonylated heterocycles useful for modulation of the progesterone receptor: Compounds of the following structure are provided, wherein n, R1-R3 and R6-R9 are defined below, as are methods of preparing and using these compounds for contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas; providing hormone replacement therapy; stimulating food intake; synchronizing estrus;... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20080221161 - Heterocyclic modulators of tgr5 for treatment of disease: Disclosed herein are compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20080221162 - Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine: The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.... Agent: Stites & Harbison Pllc

20080221163 - Selective estrogen receptor modulators: The present invention relates to a selective estrogen receptor modulator of formula I: I; or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.... Agent: Eli Lilly & Company

20080221164 - Inhibitors of sodium glucose co-transporter 2 and methods of their use: Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.... Agent: Lexicon Pharmaceuticals, Inc.

20080221165 - Use of octenidine dihydrochloride in semisolid preparations: The invention relates to the use of octenidine dihydrochloride for manufacturing a semisolid pharmaceutical composition for the treatment of wounds, atopic dermatitides, infected eczemas, dermatomycoses, vaginal infections, acne, herpes and/or for controlling multidrug-resistant pathogens, where the composition comprises from 0.005 to 5% by weight octenidine dihydrochloride, and a corresponding composition.... Agent: Young & Thompson

20080221166 - Aminoamides as orexin antagonists: e

20080221168 - N-thio-anthranilamid compounds and their use as pesticides: N-Thio-anthranilamid compounds of Formula (I) wherein is a group selected from A1 and A2 wherein the variables and the indices are as defined per the description, processes for preparing the compounds (I), pesticidal compositions comprising compounds (I), use of compounds (I) for the control of insects, acarids or nematodes, and... Agent: Hutchison Law Group Pllc

20080221167 - Selective insecticides based on haloalkylnicotinic acid derivatives, anthranilic acid diamides, or phthalic acid diamides and safeners: T

20080221169 - Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080221170 - Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia: The present invention provides methods of treating fibromyalgia or other diseases or conditions causing widespread pain and/or fatigue. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active agents, that can be used in the inventive methods. The methods of treatment... Agent: Alston & Bird LLP

20080221171 - Phenylaminopyridines: The invention relates to novel substituted 3-phenylamino-5-(3-aminophenyl)pyridines and corresponding pyrazines of formula (I), wherein A is CH, C-lower alkyl or N, R1 represents C(═O)R9, S(═O)2R10, P(═O)(OR11)2, optionally substituted phenyl or optionally substituted heteroaryl, and the other substituents have the meaning described in the specification, processes for the preparation thereof, pharmaceutical... Agent: Gibbons P.c.

20080221172 - use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection: e

20080221174 - Controlled release nisoldipine compositions: Controlled release oral dosage formulations containing calcium channel blockers, and methods of use thereof, are provided for the once-a-day treatment of cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmia. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. The formulation provides an increase in the... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080221173 - Pharmaceutical composition and a process thereof: The present invention relates to a pharmaceutical composition having dopaminergic activity and other related pharmaceutical activities comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s); a process of preparing a pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with... Agent: Fenwick & West LLP

20080221177 - 4- piridinylmethylsulphonamide derivative as fungicidal plant protection agents: e

20080221176 - Chemical compounds: This invention relates to compounds that are modulators of the liver X receptors (LXRs), and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080221175 - N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, m, n, p, and q are as defined in the description; as well as pharmaceutical compositions comprising the same, methods of use of the compounds and compositions of the invention for the treatment of conditions associated... Agent: Foley And Lardner LLP Suite 500

20080221178 - Benzimidazole derivatives,compositions containing them, preparation thereof and uses thereof: Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R1, R2, R3 and Ar are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080221179 - Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators: methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to... Agent: Philip S. Johnson Johnson & Johnson

20080221180 - Thiazole derivatives and use thereof: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080221182 - Anti-cancer and anti-microbial oxazolidinones: Disclosed herein are various novel oxazolidinone, imidazolidinone, and thiazolidinone analogs and methods of treating cancer and/or microbial infection using these analogs. Particular 4-oxazolidinone compounds are shown to have anti-cancer and anti-microbial activity.... Agent: Knobbe Martens Olson & Bear LLP

20080221183 - Anti-cancer and anti-microbial oxazolidinones: Disclosed herein are various novel oxazolidinone, imidazolidinone, and thiazolidinone analogs and methods of treating cancer and/or microbial infection using these analogs. Particular 4-oxazolidinone compounds are shown to have anti-cancer and anti-microbial activity.... Agent: Knobbe Martens Olson & Bear LLP

20080221181 - Compounds for treating tumors: s

20080221184 - Combined agents for treatment of glaucoma: A pharmaceutical composition for the treatment of glaucoma which comprises an angiotensin II antagonist and a prostaglandin which is unoprostone or latanoprost, and a method for treatment of glaucoma by administering the composition to a patient.... Agent: Frishauf, Holtz, Goodman & Chick, Pc

20080221185 - Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders: p

20080221186 - 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazole-2-ones and related compounds: where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedatory activity. These compounds of Formula 1 are useful as... Agent: Gabor L. Szekeres

20080221188 - New benzimidazole derivatives: e

20080221187 - N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors:

20080221189 - Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the b-type receptor of interleukin 8 and/or to a pacap type 1 receptor: The invention relates to use of metronidazole for the preparation of a pharmaceutical composition for treating pathologies involving at least one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080221190 - High purity butoconazole nitrate with specified particle size and a process for the preparation thereof: One object of the invention is high purity butoconazole nitrate of the formula (I) (I) containing maximum 0.1 wt % of chemical impurities, wherein at least 95% of the particles of the substance are below 75pm by diameter, whereas at least 99% of the particles are below 250 μm by... Agent: K.f. Ross P.c.

20080221191 - Cationic substituted benzofurans as antimicrobial agents: A method of treating a Mycobacterium tuberculosis infection in a subject in need thereof by administering to the subject an effective amount of a cationic substituted benzofuran compound. Methods of treating microbial infections, including infections from protozoan pathogens, such as Leishmania donovani, Trypanosoma brucei rhodesiense, a Trypanosoma cruzi, and Plasmodium... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080221193 - 3-amino chromane derivatives: The present invention relates to 3-amino chromane derivatives; to compositions containing such compounds; to methods of synthesizing such compounds; and to methods of using such compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety.... Agent: Wilmerhale/wyeth

20080221192 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, cSrc, TPR-Met, Tie2, MET, FGFR3,... Agent: Genomics Institute Of The Novartis Research Foundation

20080221195 - 1,2-diarylacetylene derivatives of acyltryptophanols: e

20080221194 - Novel potassium channel blockers and uses thereof: The invention relates to compounds of Formula (1) for use in modulating potassium channel activity in cells.... Agent: Scully, Scott, Murphy & Presser, P.c.

20080221196 - Pharmaceutically active isoindoline derivatives: Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with an α-(3,4-disubstituted phenyl)alkyl group and in the 4- and/or 5-position with a nitrogen-containing group are inhibitors of, and thus useful in the treatment of disease states mediated by, TNFα and phosphodiesterase. A typical embodiment is 2-[1-(3-ethoxy-4-methoxyphenyl)2-methylsulfonylethyl]4,5-diaminoisoindoline-1,3-dione.... Agent: Jones Day

20080221197 - Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions: o

20080221199 - Method for improving memory in mammals: A method for improving memory in healthy subjects is disclosed. This method makes use of melatonin receptor antagonists such as luzindole and/or K-185 to reverse the inhibitory effect of melatonin. This invention is particularly relevant among subjects that do not show signs of central nervous system disorders and wish to... Agent: Robert W Strozier, P.l.l.c

20080221198 - Novel crystalline forms of antidiabetic compounds: Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate... Agent: Merck And Co., Inc

20080221200 - Combination of organic compounds: The present invention furthermore relates to the use of such a combination for the prevention, delay of progression or treatment of diseases and disorders that may be inhibited by DPP IV inhibition, for the prevention, delay of progression or treatment of autoimmune diseases, and the disorders associated therewith, or for... Agent: Novartis Corporate Intellectual Property

20080221201 - Aryl sulfonamides useful for modulation of the progesterone receptor: Also provided are methods for preparing these compounds and methods of contraception; treating or preventing fibroids; treating or preventing uterine leiomyomata; treating or preventing endometriosis, dysfunctional bleeding, and polycystic ovary syndrome; treating or preventing hormone-dependent carcinomas; providing hormone replacement therapy; stimulating food intake; synchronizing estrus; and treating cycle-related symptoms using... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20080221202 - Steroids derivatives as selective progesterone receptor modulators: The present invention is directed to novel steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.... Agent: Philip S. Johnson Johnson & Johnson

20080221203 - Use of agonists and antagonists of beta adrenoceptors for treating arterial disease: Methods for treating and/or preventing cardiovascular diseases and diseases related thereto by administering a therapeutically effective amount of one or more first compound(s) having a beta3-adrenoceptor agonistic effect and a therapeutically effective amount of one or more second compound(s) having a beta1/beta2-adrenoceptor antagonistic effect are disclosed. The first compound(s) and... Agent: Knobbe Martens Olson & Bear LLP

20080221204 - Materials and methods for treating coagulation disorders: This invention is drawn to compounds which are more easily metabolized by the metabolic drug detoxification systems. Particularly, warfarin analogs which have been designed to include esters within the structure of the compounds are taught. The invention teaches methods of reducing the toxicity of drugs comprising the introduction of ester... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080221205 - Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same: The present invention relates to furan derivatives and pharmaceutical compositions containing them to prevent and cure osteoporosis. The furan derivatives of the present invention have effect on bone proliferation with the side effect reduced, so that they can be used for bone disease.... Agent: Jhk Law

20080221206 - Compounds derived from lidocaine, pharmaceutical compositions, use and method of treatment, prevention or inhibition of disease: The present invention relates to lidocaine derived compounds, which present less anesthetic activity than lidocaine itself, but with more anti-inflammatory and spasmolytic activity than said lidocaine as well as pharmaceutical compositions with at least one of these compounds or a salt of those as active principle and to the use... Agent: Klarquist Sparkman, LLP

20080221207 - Use of specific cyklolignans: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly. A preferred compound... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080221208 - Retinal derivatives and methods for the use thereof for the treatment of visual disorders: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.... Agent: Buchanan, Ingersoll & Rooney Pc

20080221209 - Enantiomers of amino-phenyl-acetic acid octadec-9-(z) enyl ester, their salts and their uses: Disclosed are enantiomers of amino-phenyl-acetic acid octadec-9-(Z)-enyl ester, and salts thereof, including pharmaceutical compositions, uses and a process for the manufacture thereof.... Agent: Cooper & Dunham, LLP

20080221210 - Thyroid receptor agonists: The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20080221211 - Method of treatment of neurological injury or cancer by administration of dichloroacetate: A method for treating neurological injury or cancer in a patient includes administration of a therapeutically-effective amount of dichloroacetic acid (DCA), a therapeutically-effective amount of electromagnetic radiation, or both to the patient.... Agent: Knobbe Martens Olson & Bear LLP

20080221212 - Topical formulation: There is described a topical formulation. The topical formulation includes: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate,... Agent: Patent Administrator Katten Muchin Rosenman LLP

20080221213 - Tablets comprising a high load of strontium: Tablets comprising strontium in the form of a strontium salt such as strontium malonate. The tablets are designed to contain a very high load of the strontium salt (75% w/w or more), which is especially advantageous due to the fact that strontium must be administered in relative high amounts for... Agent: Jones Day

20080221214 - Process for the preparation of \"urchym\" a urease and alpha-chymotrypsin enzyme inhibitory drug: The present invention relates to the compound N-4-nitrophenyl-N′-4′-nitrophenylurea as a urease and α-chymotrypsin (anti HCV) enzyme inhibitory drug named “Urchym”. N-4-nitrophenyl-N′-4′-nitrophenylurea is prepared and screened for their urease and α-chymotrypsin inhibition effects, the said compound, showed strong urease inhibition (IC50=1.25 μM). We found, that the same compound is also an... Agent: Nath & Associates Pllc

20080221215 - Antiviral inhibition of capsid proteins: Methods for evaluating the antiviral activity of test compounds are provided. Further aspects of the methods involve the retroviral capsid protein of HIV-1. In another aspect, methods of reducing mortality associated with AIDS with a compound that binds to the apical cleft near the C-terminal end of the N-terminal domain... Agent: Wilmerhale/boston

20080221216 - Use of modafinil to treat spasticity: The invention provides a method of reducing spasticity in a mammal involving administering modafinil or related compounds. The spasticity can be secondary to multiple sclerosis, spinal cord injury, stroke, brain injury, and other causes.... Agent: Hugh Mctavish Mctavish Patent Firm

20080221217 - Phenyl compounds and their use in the treatment of type ii diabetes: The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (xx); X is selected from CH, CF and N, R5 is selected from H, C1-C6 alkyl, C1-C6 fluoroalkyl, and —OR12, R9 is selected from H and —C(O)NR1OR11, R12 is selected from... Agent: Eli Lilly & Company

20080221219 - Oleamide-containing composition for animal consumption: This invention is directed generally to compositions (including foods, supplements, treats, toys, etc.) for animal consumption, particularly compositions that tend to aid in weight loss or reduction in weight gain, and particularly compositions that comprise oleamide. This invention also is directed generally to methods for using such compositions. This invention... Agent: Colgate-palmolive Company

20080221218 - Receptor: The present invention relates to synthetic receptors, products and methods which are useful in relation to the binding of phosphates for example in water purification and renal dialysis systems.... Agent: Troutman Sanders LLP

20080221220 - 2',4'-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents: wherein: n is independently 1, 2, 3, or 4; W is independently —C(═O)—, —CH(OH)—, or —C(═NOROX)—; ROX is independently —H or C1-3alkyl; J is independently: —H, —RE1, —C(═O)—RE2, —C(═O)—O—RE3, —C(═O)—O—S(═O)2ORE4, —C(═O)—(CH2)n—C(═O)ORE5, —C(═O)—(CH2)n—NRNE1RNE2, —C(═O)—(CH2)n—NRNE3—C(═O)RE6, —C(═O)—(CH2)n—C(═O)—NRNE4RNE5, or —P(═O)(ORE7)(ORE8); wherein each of RE1, RE2, RE3, RE4, RE5, RE6, and RE7 is independently: —H,... Agent: Michael Best & Friedrich LLP

20080221221 - Application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation/chemotherapy sensitization: Use of 2-bromo-isovanillin in the preparation of an anticancer medicament and/or radio- and chemotherapy sensitizing medicament is disclosed. The medicament for the treatment of cancers and/or for radio- and chemotherapy sensitization comprising 2-bromo-isovanillin as active ingredient provided herein has the following features: (1) low toxicity, without evident adverse effects; (2)... Agent: Venable LLP

20080221222 - Disinfectant: The invention relates to a disinfectant which comprises a special combination of biocidal phenols and, where appropriate, phenol derivatives and a keratolytic. The disinfectant is particularly suitable for controlling parasitic protozoa including their persistent forms.... Agent: Bayer Healthcare Llc

20080221223 - Methods for treating arthropods: Methods for treating arthropods comprising depositing at least one drop of a liquid formulation containing at least one surfactant on a solid surface of an arthropod at a contact angle sufficient to cause rapid and enhanced knockdown (KD) of the arthropod. The contact angle comprises an angle formed between a... Agent: James B. Raden

20080221225 - Genes associated with restenosis: The present invention identifies genes whose gene products are differentially expressed during restenosis, including de novo restenosis and in stent restenosis (ISR). Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to restenosis. Additionally, the invention describes screening methods for identifying agents... Agent: Bozicevic, Field & Francis LLP

20080221224 - Unimolecular tweezers: Macromolecules may be specially designed so that upon adsorption at a substrate, the macromolecules experience intramolecular tension at their covalent bonds due to the physical interaction of the molecular segments of the macromolecules with the substrate. As a result of the induced tension, the macromolecules may be used in a... Agent: Moore & Van Allen Pllc

20080214439 - Amino acid substituted molecules: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also... Agent: Seed Intellectual Property Law Group PLLC

20080214438 - Methods and apparatus for creating particle derivatives of hdl with reduced lipid content: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080214437 - Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases: Methods, compositions and devices are provided by the present invention for reducing activity of a natriuretic peptide receptor and other signals. Therapeutic treatments are provided by use of polynucleotides encoding a natriuretic peptide or by regulating the expression of natriuretic peptide receptor, such as NPRA and NPRC, or combinations of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080214436 - Methods and compositions for the treatment of cancer or other diseases: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080214435 - Novel cancer indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals: The present invention pertains to the use of subunits and oligomers of mannan-binding lectin (MBL) in prophylactic and/or curative treatment of an immunocompromised individual such as subjects suffering from solid tumors or haematological cancers. Solid tumors include such as female cancers, male cancers, cancers of the respiratory system, cancers of... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080214434 - Treatment of endothelial dysfunction in diabetic patients: A method for the treatment of endothelial dysfunction in a diabetic patient, including both diabetes induced macrovascular disorders and diabetes induced microvascular disorders, comprises administration, preferably parenteral administration, to the patient of an effective amount of high density lipoprotein (HDL).... Agent: Foley And Lardner LLP Suite 500

20080214441 - Insulins combinations: A pharmaceutical association or combination comprising a therapeutic effective amount of insulin or insulin analogue, and a therapeutic effective amount of a pharmaceutically acceptable betaine, in which the insulin and the betaine possibly form a chemical entity or complex, and in which the amount of betaine is adapted for controlling... Agent: Hovey Williams LLP

20080214440 - Vasoactive intestinal polypeptide compositions: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.... Agent: Kirton And Mcconkie

20080214442 - Anti-viral effect of an extract of ganoderma lucidum: Compositions and methods for the treatment viral infections in organisms, particularly flu virus. The methods and compositions of the disclosure involve the administration to mammals and immune cells of a fucose-containing glycoprotein fraction from Reishi. An extract of G. lucidum induces immune responses that are shown to induce increase survivability... Agent: Greenberg Traurig LLP (la)

20080214443 - Compositions and methods for control of insect infestations in plants: The present invention is directed to controlling pest infestation by inhibiting one or more biological functions in an invertebrate pest. The invention discloses methods and compositions for use in controlling pest infestation by feeding one or more different recombinant double stranded RNA molecules to the pest in order to achieve... Agent: Monsanto Company

20080214444 - Semi-synthetic rearranged vancomycin/desmethyl-vancomycin-based glycopeptides with antibiotic activity: Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of a rearranged vancomycin or desmethyl-vancomycin scaffold, in particular, alkylation or acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this... Agent: Beyer Weaver LLP

20080214445 - Method of treating a solid tumor disease comprising administering a combination comprising imatinib and an inhibitor of an efflux pump active at the blood brain barrier or demethyl imatinib: The invention relates to a method of treating a warm-blooded animal having a solid tumor disease comprising administering a combination which comprises (a) a N-phenyl-2-pyrimidine-amine derivative, especially N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.... Agent: Novartis Corporate Intellectual Property

20080214447 - Cyclic peptide compound: A cyclic peptide compound of the following general formula (I): Wherein R1, R2 and R3 are defined in the description, or a salt thereof. The compound (I) is useful for the prophylactic and/or therapeutic treatment of hepatitis C.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080214446 - Gene introduction efficiency enhancer: A gene transfer efficiency enhancer of the present invention which contains a histone deacetylase inhibitor (especially compound (A)) as an active ingredient is capable of enhancing gene transfer efficiency in a gene transfer mediated by an adeno-associated virus vector while retaining the advantages of the adeno-associated virus vector.... Agent: Bacon & Thomas, PLLC

20080214448 - Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (glp)-1 compound or a melanocortin-4 receptor (mc4) agonist peptide: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.... Agent: Emisphere Technologies, Inc

20080214467 - Exendins and exendin agonists modified with albumin: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more molecular weight increasing compounds, for example, albumin, polyethylene glycol polymers, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080214462 - Fix-mutant proteins for hemophilia b treatment: The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having improved FIX clotting activity. Three full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were... Agent: Baxter Healthcare Corporation

20080214460 - Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers: Photoactive materials, such as photosensitizers, are used as fluorescent markers for in vivo detection of the distribution of the injected filler material during cosmetic treatments. In one preferred embodiment, liposomal formulated temoporfin is used, as the photoactive component, in very small concentrations along with fillers for cosmetic and wound healing... Agent: Bolesh J. Skutnik Ceramoptec Industries, Inc.

20080214461 - Fviii-independent fix-mutant proteins for hemophilia a treatment: The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having factor VIII (FVIII) independent factor X (FX) activation potential. Five full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK... Agent: Baxter Healthcare Corporation

20080214451 - G protein coupled receptor agonists and antagonists and methods of use: The invention relates generally to G protein coupled receptors (GPCRs) and in particular to GPCR agonists and antagonists, use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with GPCRs, such as in treating conditions in which chemokine receptors play a... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080214456 - Lkktet and/or lkktnt peptide compositions and methods: A composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, and an ophthalmically acceptable carrier, an antimicrobially effective preservative, a tonicity agent for providing the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080214463 - Method for cell adhesion and wound healing: The present invention relates to a method for cell adhesion and wound healing with internal domains of βig-h3. Particularly, the present invention relates to the method of using recombinant proteins comprising one or more of 2nd or 4th internal domain of βig-h3 for cell adhesion and wound healing, wherein the... Agent: Jhk Law

20080214452 - Method for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt translocation: Anthracyclines-treated tumor cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclines induce the rapid, pre-apoptotic translocation of calreticulin (CRT) to the cell surface. Blockade or knock down of CRT suppressed the phagocytosis... Agent: Samuel A. Kassatly

20080214464 - Method for the production of biologically active rhngf: The present invention relates to a new rhNGF (recombinant human Nerve Growth Factor) where said rhNGF is characterized by the fact that it presents an in vitro and in vivo activity comparable to that of the native murine NGF. The present invention also relates to the process for the production... Agent: Nixon & Vanderhye, PC

20080214465 - Method of administering and using vegf inhibitors for the treatment of human cancer: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and... Agent: Regeneron Pharmaceuticals, Inc

20080214466 - Method of administering and using vegf inhibitors for the treatment of human cancer: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and... Agent: Regeneron Pharmaceuticals, Inc

20080214453 - Methods for treating inflammation: The present invention provides a method for treating inflammation in a subject which comprises administering to the subject soluble receptor for advanced glycation endproduct (sRAGE) in an amount effective to inhibit binding of advanced glycation endproducts (AGEs) to RAGE thereby treating inflammation in the subject. The present invention also provides... Agent: John P. White Cooper & Dunham LLP

20080214455 - Novel chemical compounds: This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with hYAK3 activity.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080214459 - Pharmaceutical composition containing sfcyriib: The present invention concerns pharmaceutical compositions containing one of the receptors FcγR IIa, FcγR IIb or FcγR III in a recombinantly produced, soluble form and their use to treat diseases or conditions which are caused by overshooting immune reactions and a pathologically increased formation of antibodies, in particular of autoantibodies.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080214450 - Polypeptides having antimicrobial activity and polynucleotides encoding same: The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.... Agent: Novozymes North America, Inc.

20080214458 - Synapse-specific proteins in glomeruli: The present invention identifies that glomeruli express many neuron-specific and especially synapse-specific protein similarities. In particular, the present invention identifies Rab3A expression, including the expression of altered forms, as well as expression of other synapse-specific proteins including neurotransmitter receptors. The invention further identifies that modulation of the activity of these... Agent: Marshall, Gerstein & Borun LLP

20080214457 - Treatment of patients with dysfunctional protein channels: Isolated peptides and polynucleotides are provided that can be used to treat a subject that has a genetic predisposition to, or has been diagnosed as having, a cardiac disorder related to dysfunctional sodium channels. Also provided are methods of treatment, as well as methods of predicting the occurrence of a... Agent: Calfee Halter & Griswold, LLP

20080214449 - Use of antagonists of the cbi receptor for the manufacture of a composition useful for the treatment of hepatic diseases: The invention relates to the use of antagonists to the CB1 receptor for the preparation of a composition for the treatment of hepatic diseases and preferably to the use of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide.... Agent: Dickstein Shapiro LLP

20080214454 - Use of hmgb fragments as anti-inflammatory agents: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080214468 - Bone tropic peptides: The present invention is directed to the use of bone tropic peptides identified through the use of a phage display library. More particularly, the invention is directed to compositions comprising the bone tropic peptides and methods for using such compositions to regulate osteogenesis, cell adhesion and angiogenesis, and diseases and... Agent: University Of Virginia Patent Foundation

20080214469 - Novel biologically active peptides and their new uses: Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.... Agent: EagleIPLimited

20080214470 - Pin1-modulating compounds and methods of use thereof: The invention is directed to peptide modulators of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer or neurodegenerative disease.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080214471 - Method for inhibition of viral infection: The invention is directed to inhibiting viral morphogenesis and viral infection. In particular, it concerns effecting such inhibition by inhibiting the prenylation or post prenylation reactions of a viral or host protein.... Agent: Morrison & Foerster LLP

20080214476 - Small peptides and methods for blocking ige mediated activation of an immune cell: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory... Agent: Lathrop & Gage Lc

20080214478 - Small peptides and methods for inhibiting the infiltration of eosinophils into airways: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory... Agent: Lathrop & Gage Lc

20080214477 - Small peptides and methods for inhibiting the migration of t-cells: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory... Agent: Lathrop & Gage Lc

20080214475 - Small peptides and methods for inhibiting the mucous release into airways: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory... Agent: Lathrop & Gage Lc

20080214472 - Small peptides and methods for treatment of arthritis: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory... Agent: Lathrop & Gage Lc

20080214474 - Small peptides and methods for treatment of chronic inflammatory bowel disease: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory... Agent: Lathrop & Gage Lc

20080214473 - Small peptides and methods for treatment of chronic obstruction pulmonary disease: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory... Agent: Lathrop & Gage Lc

20080214479 - Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose: A method of obtaining beneficial biological results associated with caloric restriction may be gained by administration of a composition containing at least one active agent which blocks metabolism of glucose as a source of energy in cells in glucose metabolism blocking effective amounts to an animal in need thereof.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080214480 - Method for treating sickle cell disease and sickle cell disease sequalae: The present invention is directed to methods of treating sickle cell disease and its sequelae, including vaso-occlusive crisis. The method comprises administering to a subject in need thereof a pharmaceutical composition comprising an elective amount of a polyanionic polysaccharide, such as pentosan sulfate, sulodexide, or its pharmaceutically acceptable salts thereof.... Agent: Wong, Cabello, Lutsch, Rutherford & Brucculeri, L.L.P.

20080214481 - Methods of treatment of endobronchial infections: The present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period... Agent: Chiron Corporation Intellectual Property - R440

20080214483 - Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (tgf-beta): Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-β (TGF-β) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ... Agent: Jacobson Holman PLLC

20080214489 - Aptamer-mediated intracellular delivery of oligonucleotides: Compositions and methods to mediate the intracellular and sub-cellular delivery of therapeutic, diagnostic and imaging agents, such as oligonucleotides. The compositions of the invention include nucleic acid conjugates comprising a delivery aptamer that is connected to an oligonucleotide. The delivery aptamer may be connected directly to the oligonucleotide, or may... Agent: Mintz, Levin, Cohn, Ferris, Glovskyand Popeo, P.C.

20080214485 - Method of inducing an immune response: A method is provided for inducing or enhancing an immune response in a mammal to a target polypeptide expressed in a plurality of cells of the mammal, which method comprises administering to the mammal an inhibitory nucleic acid which targets a region of a ribonucleic acid (RNA) which encodes said... Agent: Edwards Angell Palmer & Dodge LLP

20080214487 - Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents: A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11... Agent: Wolf Greenfield & Sacks, P.C.

20080214484 - Nucleic acids encoding sarcocystis neurona antigen and uses thereof: The present invention provides novel isolated nucleic acids encoding antigenic proteins derived from Sarcocystis neurona, or unique fragments thereof. In particular, the invention provides novel isolated nucleic acids encoding membrane-associated polypeptides SnSAG2, SnSAG3, and SnSAG4. Also provided are purified antigenic polypeptide fragments encoded by the novel nucleic acid sequences set... Agent: King & Schickli, PLLC

20080214482 - Retromer-based assays and methods for treating alzheimer's disease: This invention provides a method for determining whether an agent causes an increase in the expression of a retromer complex protein. This invention further provides a method for determining whether an agent causes an increase in the activity of a retromer complex. This invention also provides a method for increasing... Agent: Cooper & Dunham, LLP

20080214486 - Rnai-mediated inhibition of aquaporin 4 for treatment of iop-related conditions: RNA interference is provided for inhibition of aquaporin 4 (AQP4) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.... Agent: Alcon

20080214488 - Triggered rnai: The present application relates to methods and compositions for triggering RNAi. Triggered RNAi is highly versatile because the silencing targets are independent of the detection targets. In some embodiments, a method of silencing a target gene is provided. The method comprises providing an initiator to a cell comprising a detection... Agent: Knobbe Martens Olson & Bear LLP

20080214490 - Method of promoting cervical and vaginal secretions: The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y2 and/or P2Y4 purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as... Agent: Howery LLP

20080214491 - Methods of inhibiting the interaction between s100 and the receptor for advanced glycation end-products: A method of inhibiting an interaction between a S100 protein and the receptor for advanced glycation end-products is provided comprising administering to a subject a therapeutically effective amount of cromolyn, C5, or salt, hydrate, or solvate thereof. In some embodiments, the S100 protein is S100P. In some embodiments, the S100... Agent: Baker Botts, LLP

20080214492 - Folate based composition for treatment of the cardiovascular system: New formulations for the prevention and treatment of cardiovascular diseases arthrosclerosis and risk factors thereof including elevated cholesterol and blood pressure levels comprise phytosterols, flavones and folate, alone or in combination, along with additional compounds chosen to address some or all of the pathways which can result in cardiovascular diseases,... Agent: Venable LLP

20080214493 - Use of flavone compounds as potassium channel inhibitors: This invention provides a method for treating or preventing human atrial arrhythmia (fibrillation) using the leading flavone compound acacetin, and its derivatives and analogues that inhibit the ultra-rapidly-activating delayed rectifier potassium current (IKur or IKsus), transient outward potassium (Ito), and acetylcholine-activated potassium current (IK.ACh).... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080214494 - Method of drug delivery by carbon nanotube-chitosan nanocomplexes: Functionalized Single Wall Carbon Nanotube (SWCNT) complexed with nanochitosan for use in the delivery of bioaffecting substances and diagnostic applications. fSWCNT complexed with the chitosan NG042 were used for delivery of DNA-encoding EGFP reporter protein and peptide. The results demonstrate that shown CNT-chitosan hybrid nanoparticles exhibit significantly higher transfection efficiency... Agent: Smith Hopen, Pa

20080214495 - Heterocyclic sulfonamide derivatives as inhibitors of factor xa: The invention relates to compounds of formula (I), wherein R1 and R3 are independently selected from carbon and nitrogen; R2 is oxo or thioxo; n is 0, 1 or 2; each R10 is independently selected from hydrogen and C1-3alkyl; R4 and R5 are each selected from carbon and nitrogen, wherein... Agent: Pepper Hamilton LLP

20080214496 - Use of iron(iii) complex compounds: The present invention relates to novel therapeutic uses of iron(III) complex compounds with carbohydrates or derivatives thereof, in the preparation of a medicament for improving immune defence and/or brain performance.... Agent: Rankin, Hill & Clark LLP

20080214497 - Water dispersible policosanol cyclodextrin complex and method of its production: Disclosed is a formulation of policosanol with natural cyclodextrins resulting in a water dispersible form of policosanol. The disclosed process provides an economical commercial method for making the policosanol complex. The complex is suitable for incorporation into oral dosage forms and also in functional foods. One aspect of the present... Agent: Mueller And Smith, Lpa Mueller-smith Building

20080214498 - Solution for peritoneal dialysis: The present invention provides a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions... Agent: Jacobson Holman PLLC

20080214499 - Lipid-regulating agent and use thereof: The object of the present invention is to provide a lipid-regulating agent or a composition for regulating the amount of lipids comprising the agent. The present invention solves the above object by providing a lipid-regulating agent comprising a cyclic tetrasaccharide and/or its saccharide-derivative(s) and a composition for regulating the amount... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080214500 - Injectable cement composition for orthopaedic and dental use: The present invention relates to ceramic precursor powder compositions and chemically bonded ceramic (CBC) materials, Ca-aluminate and/or calcium silicate, and a composite biomaterial with prolonged shelf time of the precursor, suitable for orthopaedic applications with improved injectability. The present invention also relates to a method of manufacturing said cured material,... Agent: Young & Thompson

20080214501 - Bruton's tyrosine kinase activity probe and method of using: Described herein are probes for Bruton's tyrosine kinase (Btk). Such probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use.... Agent: Wilson Sonsini Goodrich & Rosati

20080214502 - Apparatus and method for dispersing insecticide: A method includes formulating an insecticide that is miscible with a liquid fuel, adding a selected amount of the insecticide to a liquid fuel, and combusting the liquid fuel and insecticide in an internal combustion engine. An apparatus for distributing an insecticide includes an internal combustion engine further including a... Agent: Mr. Peder K. Davisson, Esq. Davisson & Associates, Pa

20080214503 - Hiv integrase inhibitors: The present intention features compounds that are HIV integrase inhibitors and may be useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080214505 - Risedronate compositions and their methods of use: A method comprising orally administering to a human or other mammal a pharmaceutical composition comprising from about 65% to about 110% of the cumulative effective dose of risedronate or a pharmaceutically acceptable acid, salt, ester, solvate, or polymorph thereof according to a continuous dosing schedule of one, two, or three... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080214504 - Vitamin b6 related compounds and methods for recovery from trauma: The present invention includes a method of promoting recovery from trauma in a patient in need thereof comprising administration of a therapeutically effective amount of a vitamin B6 related compound (excluding vitamin B6), preferable compounds include pyridoxal-5′-phosphate, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxy-4,5-animal, and pyridoxine phosphate analogues.... Agent: Merchant & Gould PC

20080214506 - Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing: The present invention discloses a method of employing ion channel active compounds to delivery metabolism-enhancing molecules within the cell to promote rapid wound healing. It also develops a delivery kit for meperidine as a local anesthetic and wound healing accelerant for dental surgical use. And meperidine thus serves as a... Agent: Mathew J. Temmerman

20080214507 - Mono-and-di-phosphates of 3-(3-fluoro-4-hydroxy-phenyl)-7-hydroxy-naphthalene-1-carbonitrile: e

20080214509 - Methods for enhancing the efficacy of vascular disrupting agents: This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Vascular Disrupting Agent (e.g., a combretastatin or derivative thereof) by administering to the subject a Chemokine Receptor Antagonist (e.g., a CXCR4 antagonist) or Chemokine Antagonist (e.g., a SDF-1 antagonist) sequentially... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080214508 - Methods of administering water-soluble prodrugs of propofol: A method of administering a prodrug of propofol, preferably O-phosphonooxymethyl propofol disodium salt, comprises the subcutaneous or rectal administration of the prodrug in amounts sufficient to induce or maintain a generalized anesthetized state, a conscious sedated state, or to treat insomnia, anxiety, nausea, vomiting, pruritus, epilepsy, and a range of... Agent: Banner & Witcoff, Ltd.

20080214510 - Methods and compositions for treating meibomian gland disease: A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of... Agent: Ropes & Gray LLP

20080214511 - Tricyclic anilide spirolactam cgrp receptor antagonists: The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, J, K, T, U, V, W, X, Y, Z, R4, R5a, R5b, R5c, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment... Agent: Merck And Co., Inc

20080214512 - Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation: The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that required to inhibit ovulation together with one or more pharmaceutical aids and/or carriers. The daily... Agent: Striker, Striker & Stenby

20080214513 - Method of treating middle ear infections: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.... Agent: Alcon

20080214514 - Steroid derivatives of fullerenes: Described herein are steroid derivatives of fullerene moieties, for example fullerene derivatives in which cholesterol, or a cholesterol moiety, is attached via ester, amide, or ether bonds to one of a variety of “linkers,” e.g., chemical groups including alkyl chains and aromatic groups, which are then connected to the fullerene... Agent: Buchanan, Ingersoll & Rooney PC

20080214516 - Methods and compositions for inhibiting tumor growth: The present invention relates to novel betulinic acid derivatives with increased activity for the treatment of carcinomas and HIV diseases, a method for preparing such novel betulinic acid derivatives as well as their use as pharmaceuticals.... Agent: Fulbright & Jaworski L.L.P.

20080214517 - Modulation of the expression of estrogen receptors for the prevention or treatment of heart disease: The present invention relates to the upregulation of estrogen receptors (ER) alpha (ERα) and/or beta (ERβ) in endothelial cells and/or smooth muscle cells to prevent or treat heart disease. The upregulation is achieved through the use of recombinant DNA technology and, depending on therapeutic needs, may be performed with a... Agent: Quarles & Brady LLP

20080214515 - Process for preparing 3a(beta)-7a(beta)-dihydroxy-6a(beta)-alkyl-5beta-cholanic acid: Process for preparing 3α-7α(β)-di-hydroxy-6α(β)-alkyl-5β-cholanic acid (I) in which R is a linear or branched C1-C5 alkyl and the relative intermediates 3α-hydroxy-6β-alkyl-7-keto-5β-cholanic (VIII) and 3α-hydroxy-6α-alkyl-7-keto-5β-cholanic (IX).... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080214518 - Pharmaceutical composition comprising an anti-bacterial agent and an active ingredient selected from carveol, thymol, eugenol, borneol and carvacrol: The invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is an antibiotic.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080214519 - Chromane substituted benzimidazole derivatives as acid pump antagonists: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, B, X, R1, R2, R3, R4, R5 and R6, R7, R8 and R9 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such... Agent: Pfizer Inc.

20080214520 - 6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined... Agent: Eli Lilly & Company

20080214521 - Sensitization of drug-resistant lung caners to protein kinase inhibitors: The present invention relates to a method of treating non-small cell lung cancer with FLT-3 kinase inhibitor such as PKC412. The invention also relates to a pharmaceutical combination of a FLT-3 kinase inhibitor and an activator of permeabilization of the mitochondrial outer membrane, such as an activator of BAK. It... Agent: Novartis Corporate Intellectual Property

20080214522 - Antiviral indoles: e

20080214523 - Method for treating severe heart failure and medicament therefor: A method for treating severe heart failure, comprising administering to a patient an effective amount of a benzazepine compound (1): wherein R1 is H or halogen, R2 is OH, or —NR5R6 (R5 and R6 are H or lower alkyl, R3 is H, halogen, lower alkyl, or lower alkoxy, R4 is... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080214524 - Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor: m

20080214525 - Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5h-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease: A compound of formula (I); or a salt or solvate thereof, wherein: the dotted line indicates the optional presence of a double bond between C2 and C3; R2 is selected from —H, —OH, =0, ═CH2, —CN, —R, OR, halo, ═CH—R, O—SO2—R, CO2R and COR; R7 is selected from H, R,... Agent: Michael Best & Friedrich LLP

20080214526 - Macrocyclic compounds and compositions useful as bace inhibitors: The invention relates to novel macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 or 18, in free base... Agent: Novartis Institutes For Biomedical Research, Inc.

20080214527 - Hiv integrase inhibitors: The present invention features compounds that are HIV integrase inhibitors useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080214528 - Anti-infective agents: where R1 is cyclobutyl—N(Ra)-, n is 1, 2, 3 or 4, and at least one R5 is RaSO2N(Rj)alkyl-, In a non-limiting example, a compound of the present invention is N-[(3-{1-[(cyclobutyl)amino])-4-hydroxy -2-oxo-1,2-dihydro-quinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide. The present invention also features compositions comprising the compounds of the present invention or pharmaceutically acceptable salts, stereoisomers or... Agent: Paul D. Yasger Abbott Laboratories

20080214529 - Saturated fused [1,2-b]pyridazinone compounds: The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Connolly Bove Lodge & Hutz LLP

20080214530 - Photo-activated disinfection: The present invention relates to photo-activated disinfection. In particular, the present invention relates to photo-activated disinfection in the oral cavity. We describe a dental apparatus comprising a light source producing light at a predetermined wavelength and power, and optical transmission means to train the light from the light source onto... Agent: Connolly Bove Lodge & Hutz LLP

20080214531 - Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipdemia: Methods for the treatment of insulin resistance, diabetes, and/or diabetes associated dyslipidemia by administering niacin and meloxicam are disclosed.... Agent: Nelson Mullins Riley & Scarborough, LLP

20080214532 - Carboxanilides as microbiocides: Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080214533 - Cyclic iminocarbamates and their use: m

20080214534 - (1,10b-dihydro-2-(aminoalkyl-phenyl)-5h-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as hiv viral replication inhibitors: The present invention relates to 5H-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as inhibitors of the viral replication of the HIV virus, processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present HIV inhibitors with other anti-retroviral... Agent: Philip S. Johnson Johnson & Johnson

20080214535 - Amorphous aprepitant coprecipitates: A coprecipitate comprising amorphous aprepitant and a pharmaceutically acceptable carrier is prepared by rapidly removing solvent from a solution containing aprepitant and the carrier.... Agent: Dr. Reddy's Laboratories, Inc.

20080214536 - Amido-substituted 6-phenylphenanthridines: c

20080214537 - Bridged phenanthridines: These compounds are useful as cannabinoid receptor ligands and can be prepared as pharmaceutical compositions for the prophylaxis or treatment of a variety of diseases, disorders and conditions including inflammatory pain, visceral pain, postoperative pain, cancer pain, neuropathic pain, musculoskeletal pain, dysmenorrhea, menstrual pain, migraine, headache as well as inflammatory... Agent: Cara Therapeutics, Inc. Intellectual Property Department

20080214538 - Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics: e

20080214539 - Benzisoxazole piperidine compounds and methods of use thereof: The invention includes benzisoxazole piperidine compositions and methods of using them for modulating sleep.... Agent: Eli Lilly & Company

20080214540 - Substituted indolealkanoic acids: Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080214541 - Compositions and methods for inducing osteogenesis: The present invention provides compositions and methods for differentiating and transdifferentiating mammalian cells into cells of an osteoblast lineage.... Agent: Towmsend & Townsed & Crew LLP

20080214542 - Arylpiperazine derivatives and their use as selective dopamine d3 receptor ligands: The invention concerns compounds of general formula (I), a method for preparing same, as well as their use as therapeutic agent.... Agent: Stites & Harbison PLLC

20080214543 - N-phenyl-(2r,5s)dimethylpiperazine derivative: The present invention relates to a novel N-phenyl-(2R,5S)dimethylpiperazine derivatives useful as antiandrogenic agent which exhibits a sufficient prostate gland reducing effect as compared with conventional compounds and are excellent in oral activity. The compound of the present application is useful in preventing or treating prostate cancer, benign prostatic hyperplasia, and... Agent: Sughrue-265550

20080214544 - Substituted heterocycles and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as c-met mediated diseases and/or HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the... Agent: Amgen Inc.

20080214545 - Substituted pyrazolyl urea derivatives useful in the treatment of cancer: The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).... Agent: Millen, White, Zelano & Branigan, P.C.

20080214547 - Methods and compositions of trail-death receptor agonists/activators: This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The... Agent: Fulbright & Jaworski L.L.P.

20080214546 - N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase: The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.... Agent: Fish & Richardson PC

20080214548 - 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors: and salts thereof, to a process for their manufacture, to their use in the treatment of (especially cysteine protease, such as UCH-L3- and/or USP-2 dependent) diseases or for the manufacture of pharmaceutical formulations against these diseases, methods of treatment of warm-blooded animals comprising administering the compounds and/or their salts to... Agent: Novartis Institutes For Biomedical Research, Inc.

20080214549 - N-substituted glycine derivatives: hydroxylase inhibitors: d

20080214550 - Novel inhibitors of folic acid-dependent enzymes: wherein R1=—NH2 or —OH, and C and D are each, independently, a 5- or 6-membered, substituted or unsubstituted, aromatic or non-aromatic ring which may also contain one or more heteroatoms, and C is connected to group B in any available position.... Agent: Wolf Greenfield & Sacks, P.C.

20080214551 - Treatment of burns: The present invention provides methods of treatment of burns, which comprise the step of applying to the burns of a subject a therapeutically effective amount of a metal ion chelating agent.... Agent: Myers Bigel Sibley & Sajovec

20080214552 - Substituted pyridazinecarboxamides and derivatives thereof: e

20080214553 - 2-(4-oxo-4h-quinazolin-3-yl) acetamides and their use as vasopressin v3 antagonists: The present invention relates to 2-(4-oxo4H-quinazolin-3-yl)acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080214557 - Method for preparation of pharmaceutical composition having improved disintegratability and pharmaceutical composition manufactured by same method: There exists a strong desire both for pharmaceutical compositions which rapidly exhibit pharmacological effects without an increase in the size of the dosage form or a decline in quality due to interactions between a pharmaceutically active ingredient and the disintegrant, and also for a method of preparing such pharmaceutical compositions.... Agent: Birch Stewart Kolasch & Birch

20080214554 - Methods for preventing or treating cardiac arrhythmia: Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof.... Agent: Duane Morris LLP

20080214555 - Use of ranolazine for the treatment of cardiovascular diseases: Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.... Agent: Cv Therapeutics, Inc.

20080214556 - Use of ranolazine for the treatment of cardiovascular diseases: Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.... Agent: Cv Therapeutics, Inc.

20080214558 - Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors: Pyrimidine-2,4-diamines derivatives having activity as JAK2 kinase inhibitors are disclosed, as well as pharmaceutical compositions and methods for using the same in the treatment of cancer and other JAK2 kinase-associated conditions.... Agent: Seed Intellectual Property Law Group PLLC

20080214559 - Compounds with a combination of cannabinoid cb1 antagonism and serotonin reuptake inhibition: r

20080214560 - Use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease:

20080214561 - Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((s)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone: The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080214562 - Chemical compounds: The present invention provides compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to a chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a target cell.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080214563 - Benzimidazole thiophene compounds as plk modulators: The present invention provides 5-heteroaryl substituted benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080214566 - Amorphous ziprasidone mesylate: Provided is amorphous form of ziprasidone mesylate and process for its preparation. Also provided is a process for preparing ziprasidone mesylate dihydrate needle crystals.... Agent: Kenyon & Kenyon LLP

20080214565 - Oxazolidinone derivatives as antimicrobials: The present invention relates to certain substituted phenyl oxazolidinones of formula I and H and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of... Agent: Ranbaxy Inc.

20080214567 - Benzimidazole thiophene compounds: The present invention provides benzimidazole thiophene compounds, pharmaceutical compositions containing the same, and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080214568 - Pharmaceutical combination comprising an antifungal agent and an active substance selected from carveol, eugenol, thymol, borneol, carvacrol, and alpha- and beta-ionones: The present invention relates to a pharmaceutical composition. The inventive pharmaceutical composition comprises: at least a first therapeutically-active substance which is selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone and the isomers, derivatives and mixtures thereof; and at least a second therapeutically-active substance which is an antifungal agent.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080214564 - Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same: The present invention provides the compound of formula (I) in a solid form which, as a bulk medicament for pharmaceutical manufacture, is uniform, has a high purity, and is easy to work with. The invention further provides a process for preparing this compound, and pharmaceutical compositions containing the same. A... Agent: Birch Stewart Kolasch & Birch

20080214569 - Use of phosphatases to treat tumors overexpressing n-cor: This invention provides a method of treating a patient suffering from a tumor overexpressing N—CoR comprising administering to the patient a phosphatase ligand, alone or in combination with a retinoid receptor ligand, a histone deacetylase ligand, or both, in amounts effective to treat the patient. This invention also provides a... Agent: Cooper & Dunham, LLP

20080214571 - Novel compounds: Disclosed is a method for use of phenyl sulfone compounds of formula (I) in the treatment of anxiety.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw 2220

20080214570 - Therapeutic agents: The present invention relates to compounds of formula I and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080214572 - Selected tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain: e

20080214573 - Compounds useful for inhibiting chk1: Substituted urea compounds useful in the treatment of diseases and C1-3alkyleneOR3 conditions related to DNA damage or lesions in DNA replication are disclosed formula (I), wherein X1 is null, —O—, —S—, —CH2—, or —N(R1)—; X2 is —O—,. -£>.-, or —N(R1)—, -.. Y xs 0 or S; or =y represents two... Agent: Eli Lilly & Company

20080214574 - Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders: b

20080214575 - Piperidine derivatives useful as ccr5 antagonists: or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R9, R10, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080214576 - Topoisomerase inhibitors and prodrugs: Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.... Agent: Townsend And Townsend And Crew, LLP

20080214577 - New compounds 320: m

20080214578 - Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives 793: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080214579 - Thienopyrimidinediones and their use in the modulation of autoimmune disease: e

20080214580 - 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression: The present invention provides novel purinones and purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulae I and II:... Agent: Heslin Rothenberg Farley & Mesiti PC

20080214581 - Purine derivatives as agonists of the adenosine a2a receptor: e

20080214582 - Purine derivatives as inhibitors of receptor tyrosine kinase activity: Compounds of the formula (I), in which R1, R2, R3, R4 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.... Agent: Baker & Daniels LLP

20080214583 - 7h-pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent: The invention relates to new 7H-pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for producing the active agent. The pharmaceutical preparation is adventageously antiphlogistic and analgetic one, a preparation reducing neuropathic hyperalgesia and rheumatic arthritis, a preparation for hindering destruction of bones chondrus,... Agent: Young & Thompson

20080214584 - Method for treating cancer: The present invention provides a method for treating cancer, which includes selecting a patient coexpressing HER2 and HER3, and administering an effective amount of a HER2 inhibitor to the patient.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080214585 - New classical antifolates: R4, R5, R6, R7, R8, and R9 independently are H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, acyl, —C(O)-alkyl, —C(O)-alkenyl, or —C(O)—alkynyl; as well as pharmaceutically acceptable esters, amides, salts, solvates, and prodrugs thereof. The compounds are useful in pharmaceutical compositions and in methods of treating multiple conditions,... Agent: Alston & Bird LLP

20080214586 - 2-amino-4-phenylquinazoline derivatives and the use thereof as hsp90 modulators: Novel phenylquinazoline derivatives of the formula (I), in which R1, R2, R3, R4 and R5 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays... Agent: Millen, White, Zelano & Branigan, P.C.

20080214587 - Processes for the preparation of azoxystrobin using dabco as a catalyst and novel intermediates used in the processes: The present invention relates, inter alia, to a process for preparing a compound of formula (I): which comprises either (a) reacting a compound of formula (II): with 2-cyanophenyl, or a salt thereof, in the presence of between 0.1 and 2 mol % of 1,4-diazabicyclo[2.2.2]octane, or (b) reacting a compound of... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080214588 - Hiv inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines: HIV replication inhibitors of formula (I) pharmaceutically acceptable addition salts; or stereochemically isomeric forms thereof, wherein R1 is halo; R2 and R3 each independently are C1-6alkyl; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.... Agent: Philip S. Johnson Johnson & Johnson

20080214589 - Thrombin inhibiting 2,4-dioxo-3,4-dihydropyrimidine derivatives: There is provided a compound of formula I wherein R1 to R5, A, G, L and X have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of... Agent: Pepper Hamilton LLP

20080214590 - Zalcitabine (ddc) boosted lamivudine (3tc) compositions for antiretroviral therapy: Boosted cytidine analogue reverse transcriptase inhibitor antiretroviral compound is a new therapeutic anti HIV option, in combination with another drug such as a NRTI or a protease inhibitor. It's heightened and sustained antiretroviral potency is due to the increased intracellular level of 3TC triphosphate, the active form of 3TC. This... Agent: Bereskin And Parr

20080214591 - N-aryl diazaspirocyclic compounds and methods of preparation and use thereof: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080214592 - Methods of treating anxiety disorders: Disclosed are methods of treating an anxiety disorder, e.g., obsessive compulsive disorder, in an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to restore normal monoaminergic tone within the synapse.... Agent: Knobbe Martens Olson & Bear LLP

20080214593 - Tetracyclic amino and carboxamido compounds and methods of use thereof: The present invention relates to Tetracyclic Amino Compounds and Tetracyclic Carboxamido Compounds, compositions comprising an effective amount of a Tetracyclic Amino Compound or a Tetracyclic Carboxamido Compound and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes, a diabetic complication, reoxygenation injury resulting from organ transplantation, an... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080214594 - Inhibitors of checkpoint kinases: The instant invention provides for compounds which comprise fused pyrazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.... Agent: Merck And Co., Inc

20080214596 - Biomarkers for sensitivity of proliferative diseases to mtor inhibitors: Disclosed is a method for determining the sensitivity of a proliferate disease in a subject to treatment with an mTOR inhibitor, comprising determining the level of expression and/or phosphorylation state of S6 in a sample derived from the subject, as well as related methods of treatment and uses.... Agent: Novartis Corporate Intellectual Property

20080214595 - Use of rapamycin derivatives for the treatment and/or prevention of cardiovas cular disorders: The present invention provides methods of treating and/or preventing cardiovascular disorders comprising administering rapamycin derivative compounds.... Agent: Novartis Corporate Intellectual Property

20080214597 - Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors: e

20080214598 - Novel piperidine carboxylic acid amide derivatives: The invention relates to novel piperidine carboxylic acid amide derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of these novel compounds, pharmaceutical compositions comprising such compounds and especially the use of such compounds as... Agent: Hoxie & Associates LLC

20080214599 - Use of par-1/par-4 inhibitors for treating or preventing vascular diseases: Use of a compound of formula (I) or a compound selected from the group consisting of a prasugrel metabolite, clopidogrel, a clopidogrel metabolite, ticlopidine, a ticlopidine metabolite, cangrelor, a cangrelor metabolite, AZD-6140, and an AZD-6140 metabolite for the treatment of and/or prevention of coagulation induced vascular diseases and recurrence thereof... Agent: Eli Lilly & Company

20080214601 - 2-alkylbenzoxazole carboxamides as 5ht3 modulators: e

20080214602 - N-biarylamides: The invention relates to N-biarylamides useful for the prophylaxis and/or treatment of impairments of perception, concentration, learning and/or memory, and to processes for preparing them, and pharmaceutical compositions containing them.... Agent: Edwards Angell Palmer & Dodge LLP

20080214600 - Quaternized quinuclidine esters: wherein the different substituents and/or radicals have the values defined in the claims. The invention also relates to a process for the preparation of said compounds, to pharmaceutical compositions comprising them, as well as to combinations of said compounds with other compounds which are active in the treatment of respiratory,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080214603 - 5-ht7 receptor antagonists: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is... Agent: Morgan & Finnegan, L.L.P.

20080214605 - Alkyl sulfoxide quinolines as nk-3 receptor ligands: e

20080214604 - Medicinal composition: A pharmaceutical composition comprising: an active ingredient consisting of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, salt thereof, or solvate of the foregoing; and (i) a compound, a 5% (w/w) aqueous solution or suspension of which has a pH of 8 or more, and/or (ii) silicic acid, salt thereof, or solvate of the foregoing is a... Agent: Birch Stewart Kolasch & Birch

20080214606 - Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells: The present invention relates to novel methods for the identification of compounds useful for the treatment of drug resistance, and to novel treatment methods using the identified compounds.... Agent: Klarquist Sparkman, LLP

20080214607 - Heteroaromatic quinoline compounds: The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in... Agent: Pfizer Inc Steve T. Zelson

20080214608 - New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments: This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydrates, prodrugs, polymorphs and pseudopolymorphs thereof, to their preparation, to their compositions and to their use.... Agent: Ladas & Parry

20080214609 - Development of new selective estrogen receptor modulators: The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.... Agent: Woodcock Washburn LLP

20080214611 - Pharmaceutical compositions - 659: The invention relates to a process for the preparation of a stable dispersion of amorphous particles of a CB1 modulator of sub-micron size in an aqueous medium.... Agent: Morgan Lewis & Bockius LLP

20080214610 - Thiazolylimidazole derivatives and their use as inhibitors of microsmal triglyceride transfer protein: The present invention relates to thiazolylimidazole derivatives of the general formula (I) in which: G represents a bond or a divalent radical chosen from the groups g1, g2 and g3; and R1, R2, R3, R4, R5, R6, Y and Z are as defined in the description. Application of the compounds... Agent: Millen, White, Zelano & Branigan, P.C.

20080214612 - Selective estrogen receptor modulators containing a phenylsulfonyl group: The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.... Agent: Eli Lilly & Company

20080214614 - Cytoskeletal active rho kinase inhibitor compounds, composition and use: The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated... Agent: Howery LLP

20080214613 - Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity: The present invention relates to benzimidazole compounds having dual nitric oxide synthase (NOS) inhibitory activity and agonist activity at the mu-opioid receptor, to pharmaceutical and diagnostic compositions containing them, and to their medical use, particularly as compounds for the treatment or prevention of chronic pain, acute pain, migraine, and neuropathic... Agent: Clark & Elbing LLP

20080214615 - N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same: This invention relates to N-methylaminomethyl-isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.... Agent: Jones Day

20080214616 - Pyridine derivatives as dipeptedyl peptidase inhibitors: The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C1-C6 fluoroalkyl, and —OR12; R9 is selected from H —NR13C(O)R14 and —C(O)NR10R11; R12 is selected from H,... Agent: Eli Lilly & Company

20080214617 - Carbamate compounds: Carbamate compounds having a structure represented by formula I (where R1, R2, R3, R4, R5 and R6 are as defined herein) are useful as anti-tumor agents.... Agent: Bristol-myer Squibb Company

20080214619 - Business method to treat and/or prevent a gastric acid disorder with a proton pump inhibitor (ppi) and a cholinergic agonist to induce rapid onset of ppi action with or without food: Pharmaceutical proton pump inhibitor (PPI) medications and methods are disclosed for preventing and/or treating gastrointestinal disorders characterized by abnormalities in gastric acid secretion at anytime of the day or night without the need for food effect or to be taken with food. The medications comprise a PPI and a cholinergic... Agent: Edwards Angell Palmer & Dodge LLP

20080214618 - Gastric therapies amd compositions therefor: 1. A composition, in one or more parts, for the treatment of gastric and/or duodenal H. pylori infections, the composition including effective amounts of: (a) a proton pump inhibitor in a systemically available dosage form; (b) a mucolytic preparation; (c) a proton pump inhibitor in a gastrically available dosage form;... Agent: Venable LLP

20080214620 - Novel inhibitors of glutaminyl cyclase:

20080214621 - Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In... Agent: Eli Lilly & Company

20080214623 - N-(2,2-dimethylpropyl)-6- -3-pyridinecarboxamide: The present invention relates to a novel compound, processes for its preparation, compositions comprising the same and its use in the treatment of condition or diseases mediated by p38 kinase activity.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080214622 - Substituted triazole derivatives as oxytocin antagonists: The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).... Agent: Pfizer Inc.

20080214624 - Fungicidal composition comprising a pyridylmethylbenzamide derivative and a thiazolecarboxamide derivative: e

20080214625 - Roflumilast for the treatment of diabetes mellitus: The invention relates to the use of Roflumilast and/or Roflumilast N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention additionally relates to combinations of Roflumilast and/or Roflumilast N-Oxide with other active agents for the treatment of diabetes mellitus.... Agent: Nath & Associates PLLC

20080214626 - Methods for prevention and treatment of diseases causes by hypertension: A method for the prevention and/or treatment of a disease caused by hypertension comprising administering to a mammal, such as a human, in need thereof pharmaceutically effective amounts of (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2′-(1H-tetrazol-5-yl(biphenyl-4-yl]methyl]imidazol-5-carboxylate and a calcium channel blocker which is amlodipine or amlodipine besylate.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080214628 - Compounds capable of activating cholinergic receptors: Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080214627 - Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA... Agent: Intrexon Corporation

20080214629 - Controlled release compositions of tizanidine: The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.... Agent: Philip S. Johnson Johnson & Johnson

20080214630 - Desferrithiocin polyether analogues: e

20080214631 - Use of riluzole for the treatment of multiple sclerosis: Methods and compositions for the treatment of multiple sclerosis comprising riluzole (6-(trifluoromethoxy)-benzothiazolamine) are disclosed herein.... Agent: Fish & Richardson

20080214633 - Alpha-form or beta-form crystal of acetanilide derivative: To provide novel crystals useful as an ingredient for the production of a diabetes remedy. The invention is concerned with α-form crystal and β-form crystal of (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide. The α-form crystal does not exhibit hygroscopicity and has stability such that it can be used as a medicine, and is useful for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080214632 - Parasiticidal compositions: The present invention relates to products comprising a macrocylic lactone and an amidine, which products are suitable for controlling parasites, in particular ectoparasites, on animals.... Agent: Bayer Healthcare LLC

20080214634 - Active substance combinations having insecticidal and acaricidal properties: The present invention relates to novel insecticidally and acaricidally active compound combinations of N2-[1,1-dimethyl-2-(methylsulphonyl)ethyl]-3-iodo-N1-{2-methyl-4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl}phthalamide of the formula (I) and the active compounds identified in the disclosure.... Agent: Bayer Cropscience Lp

20080214635 - Modulation of pathogenicity: e

20080214636 - Glycyrrhetinic acid-30-amide derivatives and their use:

20080214638 - Anthranilic acid derivatives active as the hm74a receptor: Therapeutically active anthranilic acid derivatives of Formula (I) or of Formula (Ia) wherein R, R1, R2 and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080214637 - Process for the synthesis of tetrazoles: A process for the synthesis of tetrazol derivative has been developed which starts from a tetrazole derivative where acidic hydrogen atom has been replaced by a protecting group and the deprotection is performed with a catalytic amount of organic acid and can proceed in an aqueous solvent.... Agent: Sandoz Inc

20080214639 - Leuprolide acetate and acetylcholinesterase inhibitors/nmda receptor antagonists for the treatment of alzheimer's disease: Methods of treating, mitigating, slowing the progression of, or preventing Alzheimer's Disease include administration of gonadotropin-releasing hormone analogues in combination with acetylcholinesterase inhibitors and/or N-methyl-D-aspartate receptor antagonists.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080214640 - Thrombopoietin mimetics: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080214641 - Chemical compounds 572: v

20080214642 - Fungicidal n-benzyl-5-hydroxy-5-phenylpryrazolines, processes for their preparation and compositions comprising them:

20080214643 - Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080214644 - 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri: The present invention relates to 2-(1H-indolylsulfanyl)-benzyl amine derivatives of general formula (I):... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20080214645 - Uses of 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssris: e

20080214646 - Novel nsaids possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: This invention provides a prodrug that help arthritis patients without increasing cardiovascular and gastrointestinal risk. A novel group of hybrid nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs), moiety attached via a one -carbon methylene spacer to the carboxylic acid group of the traditional NSAIDs aspirin, ibuprofen and indomethacin were synthesized. The... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20080214647 - Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1): wherein: X is a chemical bond, —CH2— or —C(O)—; R1 is alkyl, cycloalkyl, —CH2— cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl; R2 is H, alkyl, cycloalkyl, —CH2-cycloalkyl, or perfluoroalkyl; R3 is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R4 is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl,... Agent: Wyeth Patent Law Group

20080214648 - Hiv prodrugs cleavable by cd26: the stereoisomeric forms and salts thereof, wherein n is 1 to 5; Y is proline, alanine, hydroxyproline, dihydroxyproline, thiazolidinecarboxylic acid (thioproline), dehydroproline, pipecolic acid (L-homoproline), azetidinecarboxylic acid, aziridinecarboxylic acid, glycine, serine, valine, leucine, isoleucine and threonine; X is selected from any amino acid in the D- or L-configuration; X and... Agent: Philip S. Johnson Johnson & Johnson

20080214649 - Compositions and therapeutic use of n-acetyl aldosamines and n-acetylamino acids: Embodiments relate to compositions and use of compositions comprising amino acids and/or N-acetylamino acids for systemic administration to a mammal. Systemic administration is believed to alleviate or improve symptoms or syndromes associated with nervous, vascular, musculoskeletal, or cutaneous systems.... Agent: Goodwin Procter LLP

20080214651 - Crystalline forms of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1): Novel crystalline forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR,... Agent: Pfizer Inc.

20080214650 - Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel process for preparing other forms: The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.... Agent: Kenyon & Kenyon LLP

20080214652 - Methods of treating hyperlipidemia: The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080214653 - Methods and compositions for the prevention and treatment of kindney disease: The invention provides compositions for preventing or treating kidney disease and improving kidney function comprising at least two ingredients selected from the group consisting of